salicylic acid has been researched along with Alopecia Circumscripta in 295 studies
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
Excerpt | Relevance | Reference |
---|---|---|
"The efficacy of a 3 percent topical minoxidil solution (2,4-diamino-6-piperidinopyrimidine-3-oxide) in a propylene glycol-water-ethanol base applied twice daily for one year to half the scalp was evaluated in patients with severe chronic alopecia areata." | 10.16 | 3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. ( Fransway, AF; Muller, SA, 1988) |
"Although intralesional triamcinolone acetonide (TA) is the most commonly prescribed treatment for localized alopecia areata (AA), the literature regarding the optimal concentration for attaining better efficacy with the most acceptable side effects is scarce." | 9.41 | Identification of novel step-up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double-blind randomized controlled trial. ( Bains, A; Bhardwaj, A; Budania, A; Kumar-M, P; Rajan M, B; Singh, S; Thirunavukkarasu, P, 2021) |
"We sought to determine the safety, including the dose-limiting toxicities with adverse events, and efficacy, ie, response rate, of bexarotene in alopecia areata." | 9.14 | Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. ( Bassett, R; Duvic, M; Stevens, V; Talpur, R; Vu, J, 2009) |
"The combination of nonablative laser and topical minoxidil may be a good alternative therapy for AA patients, including alopecia totalis and alopecia universalis, without systemic and local side effects." | 7.91 | Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. ( Li, Y; Wang, W, 2019) |
" A treatment trial with topical immunotherapy using diphenylcyclopropenone was unsuccessful, which might be explained by both long-standing alopecia areata and the underlying immune deficiency with an impaired delayed hypersensitivity reaction." | 7.69 | Alopecia areata in a patient with candidiasis-endocrinopathy syndrome: unsuccessful treatment trial with diphenylcyclopropenone. ( Böni, R; Trüeb, RM; Wüthrich, B, 1995) |
"Ninety patients with alopecia areata were treated with weekly applications to one side of the head of dinitrochlorobenzene (DNCB) dissolved in acetone, the other side of the head serving as control region." | 7.66 | Dinitrochlorobenzene therapy for alopecia areata. ( Cebulla, K; Echternacht-Happle, K; Happle, R, 1978) |
"Anthralin 1% is an effective therapy for AA and should be continued at least 9 months." | 6.84 | Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. ( Balevi, A; Özdemir, M, 2017) |
"The efficacy of a 3 percent topical minoxidil solution (2,4-diamino-6-piperidinopyrimidine-3-oxide) in a propylene glycol-water-ethanol base applied twice daily for one year to half the scalp was evaluated in patients with severe chronic alopecia areata." | 6.16 | 3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. ( Fransway, AF; Muller, SA, 1988) |
"Although intralesional triamcinolone acetonide (TA) is the most commonly prescribed treatment for localized alopecia areata (AA), the literature regarding the optimal concentration for attaining better efficacy with the most acceptable side effects is scarce." | 5.41 | Identification of novel step-up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double-blind randomized controlled trial. ( Bains, A; Bhardwaj, A; Budania, A; Kumar-M, P; Rajan M, B; Singh, S; Thirunavukkarasu, P, 2021) |
"Alopecia areata is an autoimmune disorder characterized by the sudden development of a circumscribed patch of non-scarring hair loss on the scalp or any hair-bearing surface." | 5.36 | Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. ( Ali, A; Martin, JM, 2010) |
"We sought to determine the safety, including the dose-limiting toxicities with adverse events, and efficacy, ie, response rate, of bexarotene in alopecia areata." | 5.14 | Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. ( Bassett, R; Duvic, M; Stevens, V; Talpur, R; Vu, J, 2009) |
"The combination of nonablative laser and topical minoxidil may be a good alternative therapy for AA patients, including alopecia totalis and alopecia universalis, without systemic and local side effects." | 3.91 | Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil. ( Li, Y; Wang, W, 2019) |
"In this retrospective, cross-sectional case series, 18 patients with patchy alopecia areata treated at 4- to 8-week intervals with intralesional triamcinolone acetonide for at least 20 months were evaluated for BMD using dual-energy x-ray absorptiometry (DXA)." | 3.79 | Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids. ( Fu, JM; Harris, ST; Price, VH; Samrao, A, 2013) |
"Localized hair shedding caused by Pheidole ants is reported as a newly recognized type of hair loss, mimicking alopecia areata." | 3.72 | Localized scalp hair shedding caused by Pheidole ants and overwiew of similar case reports. ( Shamsadini, S, 2003) |
" A treatment trial with topical immunotherapy using diphenylcyclopropenone was unsuccessful, which might be explained by both long-standing alopecia areata and the underlying immune deficiency with an impaired delayed hypersensitivity reaction." | 3.69 | Alopecia areata in a patient with candidiasis-endocrinopathy syndrome: unsuccessful treatment trial with diphenylcyclopropenone. ( Böni, R; Trüeb, RM; Wüthrich, B, 1995) |
"Ninety patients with alopecia areata were treated with weekly applications to one side of the head of dinitrochlorobenzene (DNCB) dissolved in acetone, the other side of the head serving as control region." | 3.66 | Dinitrochlorobenzene therapy for alopecia areata. ( Cebulla, K; Echternacht-Happle, K; Happle, R, 1978) |
"Alopecia areata is an autoimmune hair loss disease that is non-scarring and is characterized by chronic inflammation at the hair follicle level." | 3.01 | Alopecia Areata: Current Treatments and New Directions. ( Bar, J; Dahabreh, D; Del Duca, E; Guttman-Yassky, E; Jung, S; Renert-Yuval, Y, 2023) |
" The adverse effects of ALA-PDT were mild, which indicated safety and tolerability of this treatment." | 3.01 | Treatment of androgenetic alopecia with 5-aminolevulinic acid photodynamic therapy: A randomized, placebo-controlled, split-scalp study of efficacy and safety. ( Cao, Z; Hu, W; Liu, X; Wang, P; Wang, X; Zhang, G; Zhang, L; Zhang, Y; Zhou, Z, 2021) |
"Anthralin 1% is an effective therapy for AA and should be continued at least 9 months." | 2.84 | Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. ( Balevi, A; Özdemir, M, 2017) |
"It can be severe and lead to complete hair loss of the scalp or the whole body." | 2.82 | [Janus kinase inhibitors for the treatment of alopecia areata]. ( Kobal, I; Ramot, Y, 2022) |
"The most important hair diseases are divided in non- cicatricial and cicatricial ones." | 2.72 | Common causes of hair loss - clinical manifestations, trichoscopy and therapy. ( Alessandrini, A; Bruni, F; Piraccini, BM; Starace, M, 2021) |
"The rapid rate of hair loss and disfiguration caused by the condition causes anxiety on patients and increases the risks of developing psychological and psychiatric complications." | 2.61 | Alopecia areata: A multifactorial autoimmune condition. ( Butcher, JP; Henriquez, FL; Reid, S; Simakou, T, 2019) |
"Cutaneous and systemic lupus erythematosus (SLE) commonly involves the hair and scalp." | 2.58 | Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus. ( Chanprapaph, K; Suchonwanit, P; Udompanich, S, 2018) |
"Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle." | 2.55 | Alopecia areata. ( Christiano, AM; King, LE; Messenger, AG; Pratt, CH; Sundberg, JP, 2017) |
"The non scarring form is a finding of acute systemic LE and the scarring form develops when a typical discoid lesion is located on the scalp." | 2.50 | Hair loss in autoimmune systemic diseases. ( Cozzani, E; Parodi, A, 2014) |
"Alopecia areata is a chronic inflammatory non-scarring condition affecting the hair follicle that leads to hair loss ranging from small well defined patches to complete loss of all body hair." | 2.49 | Alopecia areata: more than skin deep. ( MacLean, KJ; Tidman, MJ, 2013) |
"Based on these findings, a diagnosis of blue nevus, cellular type, was made." | 2.47 | Coexistence of giant blue nevus of the scalp with hair loss and alopecia areata. ( Ansai, S; Arase, S; Inoue, N; Kubo, Y; Murao, K; Takeichi, S, 2011) |
"Localized scalp hair loss is associated with many processes, including alopecia areata, trichotillomania, tinea capitis, and early lupus erythematosus." | 2.42 | Ant-induced alopecia: report of 2 cases and review of the literature. ( Mansouri, P; Mortazavi, M, 2004) |
"We present a case of cicatricial pemphigoid with significant scarring alopecia as a major manifestation and review our series of cicatricial pemphigoid patients in Oxford (UK)." | 2.40 | Cicatricial pemphigoid rarely involves the scalp. ( Ball, S; Walkden, V; Wojnarowska, F, 1998) |
"Alopecia areata was mimicked very closely." | 2.40 | Scalp metastases mimicking alopecia areata. First case report of placental site trophoblastic tumor presenting as cutaneous metastasis. ( Larson, JT; Lewis, EJ; Rest, EB; Wilke, MS; Yuen, YF; Zachary, CB, 1998) |
"A woman with no previous history of breast carcinoma presented with focal hair loss, which was presumptively diagnosed as alopecia areata." | 2.39 | Alopecia neoplastica simulating alopecia areata and antedating the detection of primary breast carcinoma. ( Carson, HJ; Lack, E; Pellettiere, EV, 1994) |
"A generalizable automated assessment of hair loss would provide a way to standardize measurements of hair loss across a range of conditions." | 1.91 | Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores. ( Bayramova, A; Bernardis, E; Castelo-Soccio, L; Cotsarelis, G; Gudobba, C; Mane, T; Ogunleye, TA; Rodriguez, N; Taylor, SC, 2023) |
"The most prevalent HSRDs included androgenetic alopecia (30." | 1.91 | Changing spectrum of hair and scalp disorders over the last decade in a tertiary medical centre. ( Barzilai, A; Baum, S; Galili, E; Gilboa, S; Lyakhovitsky, A; Segal, O; Tzanani, I, 2023) |
"Sarcoidosis is an idiopathic multisystem inflammatory disease that can affect virtually any part of the body." | 1.91 | Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series. ( Hosler, GA; Khalid, I; Ogwumike, E; Sode, T, 2023) |
"Granuloma annulare is a benign inflammatory illness with no known cause that might be difficult to cure." | 1.91 | Granuloma annulare with alopecia areata in a 6-year-old girl: a case report. ( Fatemeh, S; Moeine, R; Mohaghegh, F; Nekooeian, M; Saber, M; Shahriarirad, R, 2023) |
"Telogen effluvium, androgenetic alopecia, and alopecia areata are the most common forms of nonscarring alopecias." | 1.72 | Nonscarring scalp alopecia: Which laboratory analysis should we perform on whom? ( Akdeniz, N; Öner, Ü, 2022) |
"Institutions conducting research on treatment for alopecia areata can use the results of this study to better understand the needs of their target population." | 1.72 | Characterizing the willingness to undergo treatment in patients with alopecia areata. ( O'Connor, LF; Wells, KM, 2022) |
"Alopecia areata is a common non-scarring hair loss disorder." | 1.62 | Expression of survivin and p53 genes in patients with alopecia areata: A case-control study. ( Abd El-Fadeal, NM; Atef, LM; Marie, REM, 2021) |
"Six patients had progression of their hair loss in spite of treatment." | 1.62 | Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study. ( Bhoyrul, B; Jerjen, R; Pinczewski, J; Sinclair, R, 2021) |
"Scalp-hair loss was the most bothersome AA sign/symptom for most patients." | 1.56 | The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. ( Aldhouse, NVJ; Dutronc, Y; King, BA; Kitchen, H; Knight, S; Ko, JM; Macey, J; Mesinkovska, N; Nunes, FP; Wyrwich, KW, 2020) |
"Alopecia areata (AA) is an autoimmune hair loss condition that is difficult to treat and frequently disruptive to the psychosocial well-being of patients." | 1.56 | Monitoring Response to Platelet-Rich Plasma in Patients with Alopecia Areata with Optical Coherence Tomography: A Case Series. ( Chen, Z; Choi, F; Csuka, E; Ekelem, C; Heidari, AE; Hosking, AM; Juhasz, M; Mesinkovska, NA; Pham, CT; Rapaport, JA; Valdebran, M; Yu, J, 2020) |
"Alopecia areata affects not only scalp hair but also other sites of body hair, including eyebrows." | 1.56 | Eyebrows Are Important in the Treatment of Alopecia Areata. ( King, BA; Ko, JM; Liu, LY, 2020) |
"All patients named scalp hair loss as a key AA sign or symptom." | 1.56 | Development of the Scalp Hair Assessment PRO™ measure for alopecia areata. ( Aldhouse, NVJ; Dutronc, Y; King, BA; Kitchen, H; Knight, S; Ko, JM; Macey, J; Mesinkovska, N; Nunes, FP; Wyrwich, KW, 2020) |
"Of note, patchy primary scarring alopecia (SA) needs to be clearly distinguished from AA as SA can leave permanent hair loss." | 1.51 | Use of trichoscopy for the diagnosis of alopecia areata coexisting with primary scarring alopecia in a female hair loss patient. ( Fukuyama, M; Ohyama, M, 2019) |
"Tinea capitis is a scalp infection caused by different fungi." | 1.48 | A prospective study of tinea capitis in children: making the diagnosis easier with a dermoscope. ( Aqil, N; BayBay, H; Douhi, Z; Elloudi, S; Mernissi, FZ; Moustaide, K, 2018) |
"Resistance to the standard treatment for alopecia areata prompted a biopsy that proved the diagnosis." | 1.46 | Lupus erythematosus tumidus of the scalp masquerading as alopecia areata. ( Hoverson, K; Jarell, AD; Wohltmann, WE, 2017) |
" In conclusion, superficial cryotherapy is an effective and safe therapeutic modality for AA." | 1.46 | Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprehensive review of 353 cases over 22 years. ( Jun, M; Lee, NR; Lee, WS, 2017) |
"Alopecia areata was commoner in men (M:F=1." | 1.40 | An observational study of alopecia areata in Sri Lankan adult patients. ( Ranawaka, RR, 2014) |
"Alopecia areata is an autoimmune disease associated with other autoimmune diseases such as thyroid disorders, anemia, and other skin disorders." | 1.39 | Graves' disease associated with alopecia areata developing after Hashimoto's thyroiditis. ( Aşık, M; Binnetoğlu, E; Şen, H; Tekeli, Z; Ukinç, K; Uysal, F, 2013) |
"Vitiligo is caused by the destruction of melanocytes and results in the appearance of white patches on any part of the body, while alopecia areata is characterized by patchy hair loss primarily on the scalp, but may also involve other areas as well." | 1.39 | Vitiligo and alopecia areata: apples and oranges? ( Harris, JE, 2013) |
"The diagnosis of cerebriform intradermal nevus was confirmed." | 1.36 | Letter: Cerebriform intradermal nevus presenting as secondary cutis verticis gyrata. ( Alcántara González, J; Carrillo Gijón, R; Jaén Olasolo, P; Martín Diaz, RM; Truchuelo Díez, MT, 2010) |
"Alopecia areata is an autoimmune disorder characterized by the sudden development of a circumscribed patch of non-scarring hair loss on the scalp or any hair-bearing surface." | 1.36 | Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. ( Ali, A; Martin, JM, 2010) |
"Alopecia areata is considered to be a T-cell mediated autoimmune disorder." | 1.36 | Treatment of alopecia areata with 308-nm excimer lamp. ( Hasegawa, T; Ikeda, S; Ohtsuki, A, 2010) |
"Commonly occurring hair loss in children in our region is mainly acquired, and the clinical course is related to the parent's attitude to treatment, particularly for tinea capitis." | 1.34 | Hair loss in children in South-East Nigeria: common and uncommon cases. ( Maduechesi, C; Nnoruka, EN; Obiagboso, I, 2007) |
"Alopecia areata is a common form of nonscarring hair disorder of unclear etiology." | 1.33 | Alopecia areata universalis sparing nevus flammeus. ( Chen, W, 2005) |
"Scalp metastasis from breast carcinoma is reported but it is rare." | 1.33 | Multifocal scalp hair loss. ( Ebrahimi, H; Esfandiarpoor, I; Kalantari, B; Shamsadin, S; Zeinali, H, 2006) |
"We describe a female patient with linear scleroderma en coup de sabre and a longstanding clinical history of tonic and clonic convulsions." | 1.32 | Linear scleroderma en coup de sabre and brain calcification: is there a pathogenic relationship? ( Espinoza, LR; Esquivel-Valerio, JA; Flores-Alvarado, DE; Garza-Elizondo, M, 2003) |
"Alopecia areata is an autoimmune condition directed at hair follicles, which results in loss of hair." | 1.32 | Transfer of alopecia areata in the human scalp graft/Prkdc(scid) (SCID) mouse system is characterized by a TH1 response. ( Assy, B; Gilhar, A; Kalish, RS; Landau, M; Serafimovich, S; Shalaginov, R; Ullmann, Y, 2003) |
"Alopecia areata has been reported to be accompanied by abnormal autoimmune dysfunction." | 1.31 | Analysis of the expression of cutaneous lymphocyte-associated antigen on the peripheral blood and cutaneous lymphocytes of alopecia areata patients. ( Nakamura, K; Okochi, H; Tamaki, K; Yano, S, 2002) |
"Although alopecia areata is a common problem among children, many misdiagnoses for this condition can happen." | 1.31 | Striae distensae-like lesions. A cause of scarring alopecia among children. ( Al-Nuaimy, AA; Al-Waiz, MM; Sharquie, KE, 2002) |
"We studied skin biopsies from 11 untreated alopecia areata patients and two normal controls." | 1.31 | Role of cytotoxic T cells in chronic alopecia areata. ( Bodemer, C; Brousse, N; Chatenoud, L; De Prost, Y; Fraitaig, S; Peuchmaur, M, 2000) |
"Alopecia areata is a tissue restricted autoimmune condition affecting the hair follicle, resulting in hair loss." | 1.31 | Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. ( Assy, B; Gilhar, A; Kalish, RS; Landau, M; Serafimovich, S; Shalaginov, R, 2001) |
"Alopecia areata is a tissue-restricted autoimmune disease of the hair follicle, which results in hair loss and baldness." | 1.30 | Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. ( Assy, B; Berkutzki, T; Gilhar, A; Kalish, RS; Ullmann, Y, 1998) |
"Alopecia areata is a common cause of hair loss in children and adults." | 1.30 | Diagnosis: alopecia areata or not? ( Grant-Kels, JM; Hoss, DM, 1999) |
"Gonosomal aberrations such as Turner's syndrome are frequently associated with autoimmune diseases or with serological markers for autoimmune diseases." | 1.29 | [Alopecia areata and diffuse hypotrichosis associated with Ullrich-Turner syndrome. Presentation of 4 patients]. ( Gollnick, H; Müller, R; Orfanos, CE; Reupke, HJ; Tebbe, B, 1993) |
"Alopecia areata is a form of balding whose aetiology is uncertain." | 1.29 | Ultrastructural abnormalities in the dermal papillae of both lesional and clinically normal follicles from alopecia areata scalps. ( Baker, TG; Cunliffe, WJ; MacDonald Hull, SP; Nutbrown, M; Randall, VA, 1996) |
"Hair loss is a common problem likely to be encountered by a clinical practitioner." | 1.27 | Hair loss. Common congenital and acquired causes. ( Phillips, JH; Smith, SL; Storer, JS, 1986) |
"While hair loss is usually of more psychologic than physiologic significance, accurate diagnosis can be of great importance." | 1.26 | Diagnosing the common alopecias. ( Ackerman, AB; Stengel, F, 1978) |
"Sometimes male pattern baldness occurs in physiologic states, as exemplified by diffuse hair loss occasionally in the postpartum period." | 1.24 | Noncicatrizing alopecias; with special reference to alopecia areata. ( NEW, WN; NICKEL, WR, 1958) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 54 (18.31) | 18.7374 |
1990's | 45 (15.25) | 18.2507 |
2000's | 42 (14.24) | 29.6817 |
2010's | 82 (27.80) | 24.3611 |
2020's | 72 (24.41) | 2.80 |
Authors | Studies |
---|---|
Uchida, Y | 2 |
Gherardini, J | 2 |
Pappelbaum, K | 1 |
Chéret, J | 1 |
Schulte-Mecklenbeck, A | 1 |
Gross, CC | 1 |
Strbo, N | 1 |
Gilhar, A | 5 |
Rossi, A | 2 |
Funk, W | 2 |
Kanekura, T | 1 |
Almeida, L | 1 |
Bertolini, M | 3 |
Paus, R | 7 |
O'Connor, LF | 1 |
Wells, KM | 1 |
Öner, Ü | 1 |
Akdeniz, N | 1 |
Di Mascio, D | 1 |
Sapino, G | 1 |
De Maria, F | 1 |
Macey, J | 5 |
Kitchen, H | 5 |
Aldhouse, NVJ | 5 |
Edson-Heredia, E | 1 |
Burge, R | 1 |
Prakash, A | 1 |
King, BA | 7 |
Mesinkovska, N | 4 |
Guttman-Yassky, E | 8 |
Pavel, AB | 6 |
Diaz, A | 1 |
Zhang, N | 4 |
Del Duca, E | 6 |
Estrada, Y | 2 |
King, B | 1 |
Banerjee, A | 1 |
Banfield, C | 1 |
Cox, LA | 1 |
Dowty, ME | 1 |
Page, K | 1 |
Vincent, MS | 1 |
Zhang, W | 1 |
Zhu, L | 1 |
Peeva, E | 1 |
Lintzeri, DA | 1 |
Constantinou, A | 1 |
Hillmann, K | 1 |
Ghoreschi, K | 1 |
Vogt, A | 2 |
Blume-Peytavi, U | 2 |
Rafati, M | 1 |
Mahmoudian, R | 1 |
Golpour, M | 1 |
Kazeminejad, A | 1 |
Saeedi, M | 1 |
Nekoukar, Z | 1 |
Kobal, I | 1 |
Ramot, Y | 2 |
Hawwam, SA | 1 |
Ismail, M | 1 |
Elhawary, EE | 1 |
Shakshouk, H | 1 |
Tosti, A | 9 |
Wyrwich, KW | 4 |
Knight, S | 4 |
Ko, JM | 6 |
Hu, D | 1 |
Yang, S | 2 |
Lyakhovitsky, A | 1 |
Tzanani, I | 1 |
Gilboa, S | 1 |
Segal, O | 1 |
Galili, E | 1 |
Baum, S | 1 |
Barzilai, A | 1 |
Sharma, A | 1 |
Vinay, K | 1 |
Chatterjee, D | 1 |
Narang, T | 2 |
Dogra, S | 2 |
Rinaldi, F | 4 |
Pinto, D | 4 |
Borsani, E | 1 |
Castrezzati, S | 1 |
Amedei, A | 1 |
Rezzani, R | 1 |
Renert-Yuval, Y | 4 |
Facheris, P | 1 |
Pagan, AD | 1 |
Bose, S | 1 |
Gómez-Arias, PJ | 1 |
Angelov, M | 2 |
Bares, J | 1 |
Chima, M | 1 |
Estrada, YD | 4 |
Garcet, S | 1 |
Lebwohl, MG | 1 |
Krueger, JG | 6 |
Abdel Hay, R | 2 |
Sayed, KS | 2 |
Mostafa, WZ | 2 |
Afifi, HA | 2 |
Gad, LZ | 2 |
El-Samanoudy, SI | 2 |
Gudobba, C | 2 |
Mane, T | 2 |
Bayramova, A | 2 |
Rodriguez, N | 2 |
Castelo-Soccio, L | 4 |
Ogunleye, TA | 3 |
Taylor, SC | 2 |
Cotsarelis, G | 2 |
Bernardis, E | 4 |
Saber, M | 2 |
Mardani, E | 1 |
Shahmoradi, Z | 1 |
Mohaghegh, F | 1 |
Moeine, R | 1 |
Fatemeh, S | 1 |
Nekooeian, M | 1 |
Shahriarirad, R | 1 |
Sode, T | 1 |
Ogwumike, E | 1 |
Hosler, GA | 1 |
Khalid, I | 1 |
Ober-Reynolds, B | 1 |
Wang, C | 1 |
Rios, EJ | 1 |
Aasi, SZ | 1 |
Davis, MM | 1 |
Oro, AE | 1 |
Greenleaf, WJ | 1 |
Ye, Y | 2 |
Wang, Y | 1 |
Zhu, J | 1 |
Huang, R | 1 |
Yu, Q | 1 |
Zhang, J | 1 |
Chen, X | 1 |
Wei, Z | 1 |
Han, Y | 1 |
Zhou, N | 1 |
Li, P | 2 |
Li, Y | 2 |
Dahabreh, D | 3 |
Jung, S | 1 |
Bar, J | 1 |
Phillipps, J | 1 |
Pollard, B | 1 |
Mann, C | 1 |
Kokubu, H | 1 |
Kataoka, K | 1 |
Kato, T | 1 |
Fujimoto, N | 1 |
Tachibana, T | 1 |
Kang, H | 1 |
Wu, WY | 1 |
Yu, M | 1 |
Shapiro, J | 4 |
McElwee, KJ | 2 |
Liu, ZH | 1 |
Xia, XJ | 1 |
Zhi, HL | 1 |
Zhong, Y | 1 |
Sang, B | 1 |
Lv, WW | 1 |
Li, QP | 1 |
Shen, H | 1 |
Kerkemeyer, KLS | 1 |
John, JM | 1 |
Sinclair, R | 2 |
Bhoyrul, B | 2 |
Starace, M | 2 |
Guicciardi, F | 1 |
Alessandrini, A | 2 |
Baraldi, C | 1 |
Ravaioli, GM | 1 |
Bruni, F | 2 |
Piraccini, BM | 4 |
Nunes, FP | 2 |
Dutronc, Y | 3 |
Cuellar-Barboza, A | 1 |
Cardenas-de la Garza, JA | 1 |
Cruz-Gómez, LG | 1 |
Barboza-Quintana, O | 1 |
Flores-Gutiérrez, JP | 1 |
Gómez-Flores, M | 1 |
Welsh, O | 1 |
Ocampo-Candiani, J | 1 |
Herz-Ruelas, ME | 1 |
Ruano Ruiz, J | 2 |
Sanyal, RD | 1 |
Song, T | 2 |
Gay-Mimbrera, J | 2 |
Peng, X | 1 |
Phelps, RG | 1 |
Blome, C | 1 |
Calabrese, FM | 1 |
De Angelis, M | 1 |
Celano, G | 1 |
Giuliani, G | 3 |
Gobbetti, M | 1 |
Gallo, R | 1 |
Trave, I | 1 |
Parodi, A | 2 |
Rencz, F | 1 |
Carvalho, RM | 1 |
Barreto, TM | 1 |
Weffort, F | 1 |
Machado, CJ | 1 |
Melo, DF | 1 |
Lee, S | 2 |
Lee, JW | 1 |
Choe, SJ | 3 |
Koh, SB | 1 |
Ahn, YS | 1 |
Lee, WS | 6 |
Shin, JM | 1 |
Kim, KH | 2 |
Kim, SM | 1 |
Hong, D | 1 |
Park, J | 2 |
Lee, HY | 1 |
Lim, WJ | 1 |
Shin, YA | 1 |
Kim, CD | 2 |
Seo, YJ | 2 |
Lee, JH | 2 |
Kim, N | 1 |
Lee, Y | 1 |
Hardman, JA | 1 |
Nicu, C | 1 |
Tai, C | 1 |
Harries, M | 1 |
Mironov, A | 1 |
Purba, TS | 1 |
Marie, REM | 1 |
Abd El-Fadeal, NM | 1 |
Atef, LM | 1 |
Trink, A | 1 |
Sorbellini, E | 2 |
Ito, T | 2 |
Yamamoto, T | 2 |
Martin, L | 1 |
Nicolas, JF | 1 |
Hegde, P | 1 |
Relhan, V | 1 |
Sahoo, B | 1 |
Garg, VK | 1 |
Seo, S | 1 |
Serarslan, G | 1 |
Özcan, O | 1 |
Okyay, E | 1 |
Ünlü, B | 1 |
Karadağ, M | 1 |
Liu, LY | 1 |
Ekelem, C | 1 |
Juhasz, M | 1 |
Yu, J | 1 |
Hosking, AM | 1 |
Csuka, E | 1 |
Choi, F | 1 |
Pham, CT | 1 |
Heidari, AE | 1 |
Valdebran, M | 1 |
Rapaport, JA | 1 |
Chen, Z | 1 |
Mesinkovska, NA | 3 |
Nunes, F | 1 |
Mofarrah, R | 2 |
Jahani Amiri, K | 1 |
Ghasemi, M | 1 |
Seyhan, T | 1 |
Kapi, E | 1 |
Rajan M, B | 1 |
Bhardwaj, A | 1 |
Singh, S | 1 |
Budania, A | 1 |
Bains, A | 1 |
Thirunavukkarasu, P | 1 |
Kumar-M, P | 1 |
Gong, Y | 1 |
Luo, L | 1 |
Li, L | 1 |
He, X | 1 |
Lu, W | 1 |
Sha, X | 1 |
Mao, Y | 1 |
Piccolo, D | 1 |
Crisman, G | 1 |
Conforti, C | 1 |
Buzzi, M | 1 |
Genovesi, C | 1 |
Marchi, D | 1 |
Mazzaracchio, D | 1 |
Goldust, M | 1 |
Genedy, RM | 1 |
Badran, FK | 1 |
Tayae, EM | 1 |
Sabra, HN | 1 |
Glickman, JW | 2 |
Dubin, C | 2 |
Han, J | 2 |
Kimmel, GW | 2 |
Singer, G | 2 |
Chennareddy, S | 1 |
Chowdhury, M | 1 |
Zheng, AY | 1 |
Majid, I | 1 |
Sameem, F | 1 |
Sultan, J | 1 |
Aleem, S | 1 |
Jerjen, R | 1 |
Pinczewski, J | 1 |
Cao, Z | 1 |
Liu, X | 1 |
Zhang, L | 1 |
Zhang, Y | 1 |
Zhou, Z | 1 |
Zhang, G | 1 |
Wang, P | 1 |
Hu, W | 1 |
Wang, X | 1 |
Hoverson, K | 1 |
Jarell, AD | 1 |
Wohltmann, WE | 1 |
Ibrahim, O | 1 |
Bayart, CB | 1 |
Hogan, S | 1 |
Piliang, M | 1 |
Bergfeld, WF | 3 |
Nukpezah, J | 1 |
Christensen, T | 1 |
Daroach, M | 1 |
Saikia, UN | 1 |
Sachdeva, N | 1 |
Sendhil Kumaran, M | 1 |
Loh, SH | 1 |
Moon, HN | 1 |
Lew, BL | 2 |
Sim, WY | 2 |
Melé-Ninot, G | 1 |
Expósito-Serrano, V | 1 |
Quintana Codina, M | 1 |
Iglesias Sancho, M | 1 |
Sánchez-Regaña, M | 1 |
Umbert Millet, P | 1 |
Salleras Redonnet, M | 1 |
Morsy, H | 1 |
Maher, R | 1 |
Negm, D | 1 |
Udompanich, S | 1 |
Chanprapaph, K | 1 |
Suchonwanit, P | 2 |
Wen, HC | 1 |
Malik, K | 1 |
Gonzalez, J | 1 |
Hashim, PW | 1 |
Nia, JK | 1 |
Baum, D | 1 |
Kimmel, G | 1 |
Singer, GK | 1 |
Yadav, D | 1 |
Khandpur, S | 1 |
Ramam, M | 1 |
Singh, MK | 1 |
Sharma, VK | 1 |
Lee, H | 2 |
de Jong, A | 1 |
Jabbari, A | 2 |
Dai, Z | 1 |
Xing, L | 1 |
Lee, D | 1 |
Li, MM | 1 |
Duvic, M | 2 |
Hordinsky, M | 1 |
Norris, DA | 1 |
Price, V | 1 |
Mackay-Wiggan, J | 1 |
Clynes, R | 1 |
Christiano, AM | 3 |
Zhang, X | 1 |
Zhu, Z | 1 |
Yang, Y | 1 |
Cao, H | 1 |
Ling, Y | 1 |
Elmaadawy, E | 1 |
Elgarhy, LH | 1 |
Shareef, M | 1 |
Simakou, T | 1 |
Butcher, JP | 1 |
Reid, S | 1 |
Henriquez, FL | 1 |
Aqil, N | 1 |
BayBay, H | 1 |
Moustaide, K | 1 |
Douhi, Z | 1 |
Elloudi, S | 1 |
Mernissi, FZ | 1 |
Wambier, CG | 1 |
Fukuyama, M | 1 |
Ohyama, M | 2 |
Marzani, B | 1 |
Rucco, M | 1 |
Polak-Witka, K | 1 |
Rudnicka, L | 4 |
Gautam, RK | 1 |
Singh, Y | 1 |
Gupta, A | 1 |
Arora, P | 1 |
Khurana, A | 1 |
Chitkara, A | 1 |
Petukhova, L | 1 |
Patel, AV | 1 |
Rigo, RK | 1 |
Bian, L | 1 |
Verbitsky, M | 1 |
Sanna-Cherchi, S | 1 |
Erjavec, SO | 1 |
Abdelaziz, AR | 1 |
Cerise, JE | 1 |
Khademi, F | 1 |
Tehranchinia, Z | 1 |
Abdollahimajd, F | 1 |
Younespour, S | 1 |
Kazemi-Bajestani, SMR | 1 |
Taheri, K | 1 |
Wang, W | 1 |
Christmann, R | 1 |
Thomas, C | 1 |
Jager, N | 1 |
Raber, AS | 1 |
Loretz, B | 1 |
Schaefer, UF | 1 |
Tschernig, T | 1 |
Vogt, T | 1 |
Lehr, CM | 1 |
Waśkiel-Burnat, A | 1 |
Rakowska, A | 2 |
Sikora, M | 1 |
Olszewska, M | 3 |
Giuffrida, R | 2 |
Borgia, F | 2 |
Marafioti, I | 1 |
Riso, G | 1 |
Cannavò, SP | 2 |
Patruno, C | 1 |
Napolitano, M | 1 |
Ferrillo, M | 1 |
Fabbrocini, G | 1 |
Paniz Mondolfi, AE | 1 |
Cressey, BD | 1 |
Ahmad, A | 1 |
Tapia-Centola, B | 1 |
Cohen, LM | 1 |
Mahmoodi, M | 1 |
Yamakoshi, T | 1 |
Andoh, T | 1 |
Makino, T | 2 |
Kuraishi, Y | 1 |
Shimizu, T | 1 |
Missall, TA | 1 |
Hurley, MY | 1 |
Burkemper, NM | 1 |
Ekiz, O | 1 |
Sen, BB | 1 |
Rifaioğlu, EN | 1 |
Balta, I | 1 |
Harris, JE | 1 |
Lamb, RC | 1 |
Porter, M | 1 |
Taş, B | 1 |
Pilanci, Ö | 1 |
Başaran, K | 1 |
MacLean, KJ | 1 |
Tidman, MJ | 1 |
Aşık, M | 1 |
Binnetoğlu, E | 1 |
Şen, H | 1 |
Tekeli, Z | 1 |
Uysal, F | 1 |
Ukinç, K | 1 |
Cozzani, E | 1 |
McMichael, A | 1 |
Olsen, EA | 1 |
Maly, A | 1 |
Zlotogorski, A | 1 |
Carvalho, VO | 1 |
Markus, JR | 1 |
Robl, R | 1 |
Uber, M | 1 |
Abagge, KT | 1 |
Marinoni, LP | 1 |
Mubki, T | 1 |
Sato, M | 1 |
Amagai, M | 1 |
Walker, A | 1 |
Boncher, J | 1 |
Tamburro, J | 1 |
Ranawaka, RR | 1 |
Zaher, H | 1 |
Gawdat, HI | 1 |
Hegazy, RA | 1 |
Hassan, M | 1 |
Angra, K | 1 |
LaSenna, CE | 1 |
Nichols, AJ | 1 |
Yazdani Abyaneh, MA | 1 |
Raghu, P | 1 |
Kircher, K | 1 |
Kutzner, H | 1 |
Kortz, A | 1 |
Carlson, JA | 1 |
Han, YM | 1 |
Sheng, YY | 1 |
Xu, F | 1 |
Qi, SS | 1 |
Liu, XJ | 1 |
Hu, RM | 1 |
Miao, Y | 1 |
Huang, GQ | 1 |
Yang, QP | 1 |
Chu, TW | 1 |
AlJasser, M | 1 |
Alharbi, A | 1 |
Abahussein, O | 1 |
McElwee, K | 1 |
Fawzi, MM | 1 |
Mahmoud, SB | 1 |
Shaker, OG | 1 |
Saleh, MA | 1 |
Lacarrubba, F | 2 |
Micali, G | 3 |
Bansal, M | 1 |
Kumar, A | 1 |
Bansal, A | 1 |
Fuentes-Duculan, J | 1 |
Gulati, N | 1 |
Bonifacio, KM | 1 |
Kunjravia, N | 1 |
Zheng, X | 1 |
Suárez-Fariñas, M | 1 |
Shemer, A | 1 |
Devi, M | 1 |
Rashid, A | 1 |
Ghafoor, R | 1 |
Jang, YH | 2 |
Moon, SY | 2 |
Lee, WJ | 2 |
Lee, SJ | 2 |
Lee, WK | 1 |
Park, BC | 1 |
Kim, H | 1 |
Kim, DW | 1 |
Pretzlaff, M | 1 |
Sulk, M | 1 |
Bähr, M | 1 |
Reibelt, M | 1 |
Kinori, M | 2 |
Bíró, T | 1 |
Lentini, M | 1 |
Palazzo, R | 1 |
Yoshimasu, T | 1 |
Kanazawa, N | 1 |
Yamamoto, Y | 1 |
Furukawa, F | 1 |
Ardigò, M | 2 |
Agozzino, M | 1 |
Franceschini, C | 1 |
Donadio, C | 1 |
Abraham, LS | 1 |
Barbieri, L | 1 |
Sperduti, I | 1 |
Berardesca, E | 2 |
González, S | 1 |
Jin, M | 1 |
Eun, DH | 1 |
Kim, MK | 1 |
Kim, SH | 1 |
Kim, do W | 1 |
Amer, M | 1 |
Helmy, A | 1 |
Amer, A | 1 |
Jun, M | 1 |
Lee, NR | 1 |
Cohen, BE | 1 |
Bashey, S | 1 |
Cole, C | 1 |
Abraham, JL | 1 |
Ragsdale, B | 1 |
Ngo, B | 1 |
Özdemir, M | 1 |
Balevi, A | 1 |
Khunkhet, S | 1 |
Vachiramon, V | 1 |
Pratt, CH | 1 |
King, LE | 1 |
Messenger, AG | 2 |
Sundberg, JP | 1 |
Fairhurst, DA | 1 |
Mitra, A | 1 |
MacDonald-Hull, S | 1 |
Jameel, K | 1 |
Ejaz, A | 1 |
Sohail, M | 1 |
Rahman, SB | 1 |
Meyer, KC | 2 |
Brzoska, T | 1 |
Abels, C | 1 |
Yun, SJ | 1 |
Kim, HS | 1 |
Choi, JY | 1 |
Lee, JB | 1 |
Kim, SJ | 1 |
Won, YH | 1 |
Lee, SC | 1 |
Yoo, KH | 1 |
Kim, MN | 1 |
Kim, BJ | 2 |
Kim, CW | 1 |
Talpur, R | 1 |
Vu, J | 1 |
Bassett, R | 1 |
Stevens, V | 1 |
Ali, A | 1 |
Martin, JM | 1 |
Ghoreishi, M | 1 |
Martinka, M | 2 |
Dutz, JP | 1 |
Guo, HW | 1 |
Deng, J | 1 |
Yang, XC | 1 |
Zhong, BY | 1 |
Shen, Z | 1 |
Yang, SY | 1 |
Liu, BH | 1 |
Hao, F | 1 |
Müller, CS | 1 |
El Shabrawi-Caelen, L | 1 |
Ohtsuki, A | 1 |
Hasegawa, T | 1 |
Ikeda, S | 1 |
Cho, HR | 1 |
Lew, H | 1 |
Alcántara González, J | 1 |
Truchuelo Díez, MT | 1 |
Carrillo Gijón, R | 1 |
Martín Diaz, RM | 1 |
Jaén Olasolo, P | 1 |
Cameli, N | 2 |
Vincenzi, C | 2 |
Misciali, C | 2 |
Takeichi, S | 1 |
Kubo, Y | 1 |
Murao, K | 1 |
Inoue, N | 1 |
Ansai, S | 1 |
Arase, S | 1 |
Cappel, JA | 1 |
Ioffreda, MD | 1 |
Kirby, JS | 1 |
Samuelov, L | 1 |
Emelianov, VU | 1 |
Hasse, S | 1 |
Khaled, A | 1 |
Hawilo, A | 1 |
Zaouak, A | 1 |
Zeglaoui, F | 1 |
Kharfi, M | 1 |
Kamoun, MR | 1 |
Kowalska-Oledzka, E | 1 |
Slowinska, M | 1 |
Czuwara, J | 1 |
Sicinska, J | 1 |
Heng, YK | 1 |
Ng, SK | 1 |
Tan, KB | 1 |
Lee, JS | 1 |
Samrao, A | 1 |
Fu, JM | 1 |
Harris, ST | 1 |
Price, VH | 2 |
Yano, S | 1 |
Nakamura, K | 1 |
Okochi, H | 1 |
Tamaki, K | 1 |
Török, L | 1 |
Gurbity, TP | 1 |
Kirschner, A | 1 |
Krenács, L | 1 |
Claude, V | 1 |
Blanchet, P | 1 |
Grossin, M | 1 |
Hénin, D | 1 |
Kaur, I | 1 |
Kumar, B | 1 |
Flores-Alvarado, DE | 1 |
Esquivel-Valerio, JA | 1 |
Garza-Elizondo, M | 1 |
Espinoza, LR | 1 |
Sharquie, KE | 1 |
Al-Waiz, MM | 1 |
Al-Nuaimy, AA | 1 |
Shum, DT | 1 |
Lui, H | 1 |
Bernardo, O | 1 |
Landau, M | 2 |
Assy, B | 3 |
Ullmann, Y | 2 |
Shalaginov, R | 2 |
Serafimovich, S | 2 |
Kalish, RS | 3 |
Shamsadini, S | 1 |
GOLDBERG, HC | 1 |
HANFLING, SL | 1 |
NEW, WN | 1 |
NICKEL, WR | 1 |
VAMOS, L | 1 |
WINKELMANN, RK | 1 |
JAFFE, MO | 1 |
BRAUN-FALCO, O | 2 |
HASSENPFLUG, K | 1 |
BORDA, JM | 1 |
ABULAFIA, J | 1 |
ALTERAS, I | 1 |
FALK, MS | 1 |
PRINGUET, R | 1 |
Trüeb, RM | 3 |
Whiting, DA | 2 |
NICHOLAS, L | 1 |
Skali, H | 1 |
El-Ghrari, K | 1 |
Benchikhi, H | 1 |
Lakhdar, H | 1 |
Ihm, CW | 2 |
Hong, SS | 1 |
Mun, JH | 1 |
Kim, HU | 1 |
Dall'Oglio, F | 1 |
Rita Nasca, M | 1 |
Mortazavi, M | 1 |
Mansouri, P | 1 |
Brajac, I | 1 |
Gruber, F | 1 |
Petrovecki, M | 1 |
Malnar-Dragojević, D | 1 |
KNIERER, W | 1 |
Lenane, P | 1 |
Pope, E | 1 |
Krafchik, B | 1 |
Chen, W | 1 |
Raulin, C | 1 |
Gündogan, C | 1 |
Greve, B | 1 |
Gebert, S | 1 |
Choi, HJ | 1 |
Rajaratnam, R | 1 |
Balasubramaniam, P | 1 |
Marsden, JR | 1 |
Choi, CW | 1 |
Park, ES | 1 |
Huh, CH | 1 |
Shamsadin, S | 1 |
Esfandiarpoor, I | 1 |
Zeinali, H | 1 |
Kalantari, B | 1 |
Ebrahimi, H | 1 |
Sohn, KC | 1 |
Jang, S | 1 |
Choi, DK | 1 |
Lee, YS | 1 |
Yoon, TJ | 1 |
Jeon, EK | 1 |
Park, JK | 1 |
Wasyłyszyn, T | 1 |
Kozłowski, W | 1 |
Zabielski, SL | 1 |
Inui, S | 1 |
Nakajima, T | 1 |
Itami, S | 1 |
Nnoruka, EN | 1 |
Obiagboso, I | 1 |
Maduechesi, C | 1 |
Dinh, QQ | 1 |
Chong, AH | 1 |
Ito, N | 1 |
Saatoff, M | 1 |
Hashizume, H | 1 |
Fukamizu, H | 1 |
Nickoloff, BJ | 1 |
Takigawa, M | 1 |
Whiting, D | 1 |
Iorizzo, M | 1 |
Pazzaglia, M | 1 |
Igarashi, R | 2 |
Takeuchi, S | 2 |
Sato, Y | 2 |
Tonkin, N | 2 |
Chavrakov, G | 1 |
Popkhistova, E | 1 |
Ranki, A | 1 |
Kianto, U | 1 |
Kanerva, L | 1 |
Tolvanen, E | 1 |
Johansson, E | 1 |
Todes-Taylor, N | 1 |
Turner, R | 1 |
Wood, GS | 1 |
Stratte, PT | 1 |
Morhenn, VB | 1 |
Klemp, P | 1 |
Lindskov, R | 2 |
Staberg, B | 1 |
Petkov, R | 1 |
Popkhristova, E | 1 |
Nunzi, E | 1 |
Hamerlinck, F | 1 |
Cormane, RH | 1 |
Bogdanowski, T | 1 |
Rubisz-Brzezinska, J | 1 |
Bader, C | 1 |
Laugier, P | 1 |
Mcdonagh, AJ | 1 |
Snowden, JA | 1 |
Stierle, C | 1 |
Elliott, K | 1 |
Watanabe, K | 1 |
Katayama, I | 1 |
Nishioka, K | 1 |
Nutbrown, M | 5 |
Hull, SP | 2 |
Cunliffe, WJ | 5 |
Randall, VA | 5 |
Tobin, DJ | 3 |
Bystryn, JC | 1 |
Szafer, F | 1 |
Oksenberg, JR | 1 |
Steinman, L | 1 |
Sawaya, ME | 1 |
Hordinsky, MK | 1 |
Calver, NS | 1 |
Parkin, SM | 1 |
Hoffmann, R | 3 |
Wenzel, E | 1 |
Huth, A | 1 |
van der Steen, P | 1 |
Schäufele, M | 1 |
Henninger, HP | 1 |
Happle, R | 5 |
Trakimas, C | 1 |
Sperling, LC | 2 |
Skelton, HG | 1 |
Smith, KJ | 1 |
Buker, JL | 1 |
Ostertag, JU | 1 |
Hulsmans, RF | 1 |
Neumann, HA | 1 |
Carson, HJ | 1 |
Pellettiere, EV | 1 |
Lack, E | 1 |
Tebbe, B | 1 |
Gollnick, H | 1 |
Müller, R | 1 |
Reupke, HJ | 1 |
Orfanos, CE | 1 |
Perriard-Wolfensberger, J | 1 |
Pasche-Koo, F | 1 |
Mainetti, C | 1 |
Labarthe, MP | 1 |
Salomon, D | 1 |
Saurat, JH | 1 |
Silvers, DN | 1 |
Katz, BE | 1 |
Young, AW | 1 |
Ruiz-Maldonado, R | 1 |
Tamayo, L | 1 |
Durán, C | 1 |
Böni, R | 1 |
Wüthrich, B | 1 |
La Placa, M | 1 |
Placucci, F | 1 |
Gentilomi, G | 1 |
Venturoli, S | 1 |
Zerbini, M | 1 |
Musiani, M | 1 |
MacDonald Hull, SP | 1 |
Baker, TG | 1 |
Baker, BS | 1 |
Powles, A | 1 |
Garioch, JJ | 1 |
Hardman, C | 1 |
Fry, L | 1 |
Rossi, R | 1 |
Del Bianco, E | 1 |
Isolani, D | 1 |
Baccari, MC | 1 |
Cappugi, P | 1 |
Elston, DM | 2 |
McCollough, ML | 2 |
Liranzo, MO | 1 |
Heibel, M | 1 |
Hernández-Cano, N | 1 |
Pizarro, A | 1 |
Lázaro, TE | 1 |
Mayor, M | 1 |
Burón, I | 1 |
Contreras, F | 1 |
Casado, M | 1 |
Berkutzki, T | 1 |
Yuen, YF | 1 |
Lewis, EJ | 1 |
Larson, JT | 1 |
Wilke, MS | 1 |
Rest, EB | 1 |
Zachary, CB | 1 |
Krasovec, M | 1 |
Hogan, P | 1 |
Ball, S | 1 |
Walkden, V | 1 |
Wojnarowska, F | 1 |
Freyschmidt-Paul, P | 1 |
Hamm, H | 1 |
Hoss, DM | 1 |
Grant-Kels, JM | 1 |
Hwang, SM | 1 |
Choi, EH | 1 |
Lee, SH | 1 |
Ahn, SK | 1 |
Itin, PH | 1 |
Schiller, P | 1 |
Alagna, G | 1 |
Bodemer, C | 1 |
Peuchmaur, M | 1 |
Fraitaig, S | 1 |
Chatenoud, L | 1 |
Brousse, N | 1 |
De Prost, Y | 1 |
Hedstrand, H | 1 |
Ekwall, O | 1 |
Haavik, J | 1 |
Landgren, E | 1 |
Betterle, C | 1 |
Perheentupa, J | 1 |
Gustafsson, J | 1 |
Husebye, E | 1 |
Rorsman, F | 1 |
Kämpe, O | 1 |
Tsuboi, H | 1 |
Tanei, R | 1 |
Fujimura, T | 1 |
Ohta, Y | 1 |
Katsuoka, K | 1 |
Clayton, AS | 1 |
Meffert, JJ | 1 |
Toyoda, M | 1 |
Kagoura, M | 1 |
Morohashi, M | 1 |
O'goshi, K | 1 |
Iguchi, M | 1 |
Tagami, H | 1 |
Akar, A | 1 |
Arca, E | 1 |
Erbil, H | 1 |
Akay, C | 1 |
Sayal, A | 1 |
Gür, AR | 1 |
Weigand, DA | 1 |
Cebulla, K | 1 |
Echternacht-Happle, K | 1 |
Szalay, A | 1 |
Nakajima, S | 1 |
Klaber, MR | 1 |
Munro, DD | 1 |
Stengel, F | 1 |
Ackerman, AB | 1 |
Franz, E | 1 |
Pierard, GE | 2 |
De la Brassinne, M | 1 |
Montes, LF | 1 |
Ceballos, R | 1 |
Fanti, PA | 1 |
Morelli, R | 1 |
Sabattini, E | 1 |
Pileri, S | 1 |
Winton, GB | 1 |
van Baar, HM | 2 |
Perret, CM | 2 |
van Vlijmen-Willems, IM | 1 |
Cleutjens, JP | 1 |
Mackie, EJ | 1 |
Schalkwijk, J | 2 |
Hull, SM | 2 |
Thornton, MJ | 2 |
Fenton, DA | 2 |
Kendall, MD | 2 |
Zaun, H | 1 |
Höring, E | 1 |
Wienbeck, M | 1 |
Cipriani, R | 1 |
Procidano, M | 1 |
Saltarin, P | 1 |
Girolami, A | 1 |
Peserico, A | 1 |
Tanii, T | 1 |
Okada, T | 1 |
Fukai, K | 1 |
Nakagawa, K | 1 |
Hamada, T | 1 |
Rebora, A | 1 |
Fransway, AF | 1 |
Muller, SA | 2 |
Baadsgaard, O | 1 |
Clemmensen, OJ | 1 |
Piérard-Franchimont, C | 1 |
Bekhor, PS | 1 |
Gibbons, RD | 1 |
Fiedler-Weiss, VC | 1 |
West, DP | 1 |
Lapin, G | 1 |
Krueger, GG | 1 |
Phillips, JH | 1 |
Smith, SL | 1 |
Storer, JS | 1 |
Csécsei, K | 1 |
Molnár, P | 1 |
Tóth, Z | 1 |
Papp, Z | 1 |
Williams, N | 1 |
Riegert, AL | 1 |
Selmanowitz, VJ | 1 |
Orentreich, N | 1 |
Beurey, J | 1 |
Weber, M | 1 |
Bertrand, A | 1 |
Robert, J | 1 |
Mabille, H | 1 |
Burgoyne, JS | 1 |
Hundeiker, M | 1 |
Tillmann, U | 1 |
Sanderson, KV | 1 |
Hall-Smith, P | 1 |
Helm, F | 1 |
Milgrom, H | 1 |
Hönemann, W | 1 |
Höfer, W | 1 |
Dupont, A | 1 |
Reginster, JP | 1 |
Boulond, A | 1 |
Popchristov, P | 1 |
Konstantinov, A | 1 |
Obreshkova, E | 1 |
Sorni, G | 1 |
Rassner, B | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE ALOPECIA AREATA WITH A SINGLE-BLIND EXTENSION PERIOD AND A CROSS-OVER[NCT02974868] | Phase 2 | 142 participants (Actual) | Interventional | 2016-12-15 | Completed | ||
Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata[NCT03800979] | Phase 4 | 19 participants (Actual) | Interventional | 2019-01-12 | Completed | ||
Efficacy of Combined CO2 Fractional Laser With Bimatoprost 0.03% in Treatment of Alopecia Areata[NCT05600673] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
Evaluation of Trichoscopy in the Diagnosis of Tinea Capitis. Prospective, Multicenter Study (ETDT)[NCT02550496] | 104 participants (Actual) | Interventional | 2015-03-04 | Completed | |||
Barriers to Healthcare and Quality of Life for Central Centrifugal Cicatricial Alopecia Patients[NCT03044782] | 34 participants (Actual) | Observational [Patient Registry] | 2016-08-31 | Completed | |||
The Efficacy of Combining 308 Nm-Excimer Light and Topical Steroid in the Treatment of Alopecia Areata[NCT04793945] | Phase 4 | 30 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
A Pilot Study To Evaluate the Efficacy of Vytorin (Simvastatin +Ezetimibe) In the Treatment of Alopecia Areata[NCT01520077] | Phase 1 | 29 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation[NCT03473600] | Phase 4 | 40 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | ||
The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata[NCT00999869] | 20 participants (Anticipated) | Interventional | 2009-11-30 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. Score range: 0-100%. Higher score indicates more severe disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline signifies an improvement. Baseline is defined as the last measurement prior to first dosing (Day 1). (NCT02974868)
Timeframe: Baseline, Week24
Intervention | units on a scale (Least Squares Mean) |
---|---|
PF-06651600 | 32.54 |
PF-06700841 | 50.59 |
Placebo | 1.41 |
"SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Alopecia totalis (AT): derived as SALT score = 100% at baseline only. Alopecia universalis (AU): derived as SALT score = 100% and both eyelash and eyebrow assessments were none at baseline." (NCT02974868)
Timeframe: Baseline, Week 24
Intervention | units on a scale (Least Squares Mean) |
---|---|
PF-06651600-AT/AU | 27.59 |
PF-06700841-AT/AU | 48.42 |
Placebo-AT/AU | 1.81 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Week 24
Intervention | percentage of participants (Number) |
---|---|
PF-06651600 | 50.0 |
PF-06700841 | 63.8 |
Placebo | 2.1 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% confidence interval in this outcome measurement is the LSM and 90%CI for difference from initial 24-week treatment period placebo respectively. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Intervention | unit on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Week 30/ AT Week 2 | Week 32/ AT Week 4 | Week 34/ AT Week 6 | Week 36/ AT Week 8 | Week 40/ AT Week 12 | Week 44/ AT Week 16 | Week 48/ AT Week 20 | Week 52/ AT Week 24 | |
Active Non-responders on PF-06651600 | 1.76 | 1.85 | 1.80 | 2.16 | 3.35 | 3.41 | 4.70 | 7.06 |
Active Non-responders on PF-06700841 | 0.09 | 2.22 | 3.16 | 3.01 | 3.19 | 3.12 | 2.97 | 3.01 |
Placebo Non-responders on PF-06651600 | 2.99 | 3.37 | 10.16 | 8.93 | 18.30 | 25.71 | 25.28 | 28.88 |
Placebo Non-responders on PF-06700841 | -0.31 | 3.71 | 24.67 | 42.32 | 50.27 | 54.69 | 62.45 | 58.53 |
Retreated PF-06651600 Responders in the Retreatment Segment | 25.04 | 27.63 | 33.78 | 38.80 | 43.70 | 48.93 | 53.74 | 55.94 |
Retreated Responders on PF-06700841 in the Retreatment Segment | 19.83 | 15.66 | 20.09 | 27.35 | 39.28 | 50.58 | 53.79 | 58.37 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24
Intervention | units on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
PF-06651600 | -0.74 | 2.93 | 12.44 | 18.49 | 24.49 | 27.59 | 29.32 | 31.14 |
PF-06700841 | -0.93 | 7.70 | 19.37 | 29.30 | 36.57 | 41.16 | 45.55 | 49.18 |
Placebo | 1.18 | 0.85 | 1.32 | 1.77 | 1.62 | 1.61 | 1.62 | 1.41 |
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect & Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively. (NCT02974868)
Timeframe: Week 28 up to Week 52 for non-responders and responders in the withdrawal segment, AT day 1 up to AT Week 24 for retreatment segment (AT=active treatment)
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
With abnormalities without regard to baseline | Meeting Retest Criteria | Meeting Discontinuation Criteria | |
Active Non-responders on PF-06651600 | 13 | 3 | 0 |
Active Non-responders on PF-06700841 | 4 | 2 | 0 |
Non-Retreated PF-06651600 Responders in the Withdrawal Segment | 6 | 2 | 0 |
Non-Retreated PF-06700841 Responders in the Withdrawal Segment | 7 | 3 | 0 |
Placebo Non-responders on PF-06651600 | 11 | 5 | 0 |
Placebo Non-responders on PF-06700841 | 11 | 7 | 0 |
Retreated PF-06651600 Responders in the Retreatment Segment | 11 | 4 | 1 |
Retreated PF-06651600 Responders in the Withdrawal Segment | 9 | 0 | 0 |
Retreated PF-06700841 Responders in the Withdrawal Segment | 10 | 2 | 0 |
Retreated Responders on PF-06700841 in the Retreatment Segment | 14 | 4 | 0 |
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect & Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively. (NCT02974868)
Timeframe: Baseline up to Week 24
Intervention | Participants (Count of Participants) | |||
---|---|---|---|---|
With abnormalities without regard to baseline | Meeting Safety Criteria | Meeting Retest Criteria | Meeting Discontinuation Criteria | |
PF-06651600 | 35 | 12 | 5 | 0 |
PF-06700841 | 36 | 29 | 18 | 3 |
Placebo | 32 | 5 | 9 | 0 |
An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. (NCT02974868)
Timeframe: COE day 1 up to end of study
Intervention | Participants (Count of Participants) | |
---|---|---|
TEAE (All Causalities) | TEAE (Treatment Related) | |
COE-PF-06651600 | 4 | 2 |
COE-PF-06700841 | 9 | 3 |
"An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. Arms end with withdrawal Segment and retreatment segment described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder directly entered the retreatment segment and skipped the withdrawal segment." (NCT02974868)
Timeframe: Week 28 up to Week 52
Intervention | Participants (Count of Participants) | |
---|---|---|
TEAE (All Causalities) | TEAE (Treatment Related) | |
Active Non-responders on PF-06651600 | 8 | 5 |
Active Non-responders on PF-06700841 | 4 | 0 |
Non-Retreated PF-06651600 Responders in the Withdrawal Segment | 4 | 0 |
Non-Retreated PF-06700841 Responders in the Withdrawal Segment | 6 | 0 |
Placebo Non-responders on PF-06651600 | 12 | 1 |
Placebo Non-responders on PF-06700841 | 10 | 1 |
Retreated PF-06651600 Responders in the Retreatment Segment | 11 | 2 |
Retreated PF-06651600 Responders in the Withdrawal Segment | 3 | 1 |
Retreated PF-06700841 Responders in the Withdrawal Segment | 9 | 3 |
Retreated Responders on PF-06700841 in the Retreatment Segment | 9 | 2 |
An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. (NCT02974868)
Timeframe: baseline up to Week 24
Intervention | Participants (Count of Participants) | |
---|---|---|
TEAE (All Causalities) | TEAE (Treatment Related) | |
PF-06651600 | 32 | 13 |
PF-06700841 | 36 | 20 |
Placebo | 35 | 14 |
Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect & Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively. (NCT02974868)
Timeframe: COE day 1 up to end of study
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
With abnormalities without regard to baseline | Meeting Retest Criteria | Meeting Discontinuation Criteria | |
COE-PF-06651600 | 5 | 1 | 0 |
COE-PF-06700841 | 11 | 6 | 0 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Percent change from baseline is defined as SALT baseline value minus SALT value at a specific visit divided by baseline and multiplying by 100. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24
Intervention | percent change (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
PF-06651600 | -0.76 | 3.99 | 15.88 | 23.22 | 30.99 | 35.14 | 37.31 | 39.67 |
PF-06700841 | -1.13 | 9.70 | 22.88 | 34.78 | 44.17 | 49.99 | 55.46 | 59.71 |
Placebo | 1.26 | 0.53 | 1.02 | 1.31 | 0.99 | 0.86 | 0.91 | 0.43 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Intervention | percentage of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Week 30/ AT Week 2 | Week 32/ AT Week 4 | Week 34/ AT Week 6 | Week 36/ AT Week 8 | Week 40/ AT Week 12 | Week 44/ AT Week 16 | Week 48/ AT Week 20 | Week 52/ AT Week 24 | |
Active Non-responders on PF-06651600 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Active Non-responders on PF-06700841 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Placebo Non-responders on PF-06651600 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Placebo Non-responders on PF-06700841 | 0.0 | 0.0 | 0.0 | 0.0 | 8.3 | 8.3 | 8.3 | 8.3 |
Retreated PF-06651600 Responders in the Retreatment Segment | 0.0 | 0.0 | 0.0 | 0.0 | 7.1 | 7.1 | 7.1 | 14.3 |
Retreated Responders on PF-06700841 in the Retreatment Segment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13.3 | 20.0 | 20.0 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24
Intervention | percentage of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
PF-06651600 | 0.0 | 0.0 | 0.0 | 0.0 | 2.1 | 2.1 | 4.2 | 12.5 |
PF-06700841 | 0.0 | 0.0 | 0.0 | 2.1 | 6.4 | 8.5 | 12.8 | 12.8 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Intervention | percent of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Week 30/ AT Week 2 | Week 32/ AT Week 4 | Week 34/ AT Week 6 | Week 36/ AT Week 8 | Week 40/ AT Week 12 | Week 44/ AT Week 16 | Week 48/ AT Week 20 | Week 52/ AT Week 24 | |
Active Non-responders on PF-06651600 | 4.1 | 4.1 | 4.1 | 4.1 | 10.4 | 10.4 | 10.4 | 10.4 |
Active Non-responders on PF-06700841 | -2.1 | -2.1 | -2.1 | -2.1 | -2.1 | -2.1 | -2.1 | -2.1 |
Placebo Non-responders on PF-06651600 | 3.8 | 9.6 | 21.4 | 21.4 | 27.3 | 33.2 | 39.0 | 27.3 |
Placebo Non-responders on PF-06700841 | -2.1 | 14.5 | 31.2 | 56.2 | 81.2 | 64.5 | 64.5 | 64.5 |
Retreated PF-06651600 Responders in the Retreatment Segment | 47.9 | 62.2 | 69.3 | 69.3 | 62.2 | 62.2 | 69.3 | 55.0 |
Retreated Responders on PF-06700841 in the Retreatment Segment | 31.2 | 11.2 | 31.2 | 44.5 | 51.2 | 51.2 | 51.2 | 51.2 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24
Intervention | percentage of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
PF-06651600 | -2.1 | 6.2 | 18.7 | 25.0 | 39.5 | 45.8 | 47.9 | 47.9 |
PF-06700841 | -2.1 | 12.8 | 27.7 | 38.3 | 48.9 | 55.3 | 59.6 | 61.7 |
Placebo | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Intervention | percentage of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Week 30/ AT Week 2 | Week 32/ AT Week 4 | Week 34/ AT Week 6 | Week 36/ AT Week 8 | Week 40/ AT Week 12 | Week 44/ AT Week 16 | Week 48/ AT Week 20 | Week 52/ AT Week 24 | |
Active Non-responders on PF-06651600 | 0.0 | 0.0 | -2.1 | -2.1 | -2.1 | -2.1 | 4.1 | 4.1 |
Active Non-responders on PF-06700841 | 0.0 | 0.0 | -2.1 | -2.1 | -2.1 | -2.1 | -2.1 | -2.1 |
Placebo Non-responders on PF-06651600 | 0.0 | 0.0 | 9.6 | 3.8 | 15.5 | 21.4 | 27.3 | 27.3 |
Placebo Non-responders on PF-06700841 | 0.0 | 0.0 | 31.2 | 56.2 | 56.2 | 64.5 | 64.5 | 64.5 |
Retreated PF-06651600 Responders in the Retreatment Segment | 14.3 | 21.4 | 26.4 | 33.6 | 47.9 | 47.9 | 47.9 | 47.9 |
Retreated Responders on PF-06700841 in the Retreatment Segment | 20.0 | 6.7 | 11.2 | 24.5 | 44.5 | 44.5 | 37.9 | 44.5 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24
Intervention | percentage of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
PF-06651600 | 0.0 | 0.0 | 10.4 | 18.7 | 27.0 | 33.3 | 33.3 | 37.5 |
PF-06700841 | 0.0 | 10.6 | 17.0 | 29.8 | 36.2 | 40.4 | 46.8 | 51.1 |
Placebo | 0 | 0 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Intervention | percentage of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Week 30/ AT Week 2 | Week 32/ AT Week 4 | Week 34/ AT Week 6 | Week 36/ AT Week 8 | Week 40/ AT Week 12 | Week 44/ AT Week 16 | Week 48/ AT Week 20 | Week 52/ AT Week 24 | |
Active Non-responders on PF-06651600 | 0.0 | 0.0 | 0.0 | -2.1 | -2.1 | -2.1 | -2.1 | 4.1 |
Active Non-responders on PF-06700841 | 0.0 | 0.0 | 0.0 | -2.1 | -2.1 | -2.1 | -2.1 | -2.1 |
Placebo Non-responders on PF-06651600 | 0.0 | 0.0 | 0.0 | -2.1 | 3.8 | 15.5 | 15.5 | 27.3 |
Placebo Non-responders on PF-06700841 | 0.0 | 0.0 | 8.3 | 22.9 | 39.5 | 56.2 | 64.5 | 64.5 |
Retreated PF-06651600 Responders in the Retreatment Segment | 0.0 | 7.1 | 14.3 | 26.4 | 26.4 | 26.4 | 28.6 | 33.6 |
Retreated Responders on PF-06700841 in the Retreatment Segment | 0.0 | 0.0 | 6.7 | 17.9 | 31.2 | 37.9 | 37.9 | 37.9 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24
Intervention | percentage of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
PF-06651600 | 0.0 | 0.0 | 8.3 | 12.5 | 16.6 | 20.8 | 25.0 | 27.0 |
PF-06700841 | 0.0 | 0.0 | 10.6 | 23.4 | 27.7 | 31.9 | 38.3 | 40.4 |
Placebo | 0 | 0 | 0 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
Intervention | percentage of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Week 30/ AT Week 2 | Week 32/ AT Week 4 | Week 34/ AT Week 6 | Week 36/ AT Week 8 | Week 40/ AT Week 12 | Week 44/ AT Week 16 | Week 48/ AT Week 20 | Week 52/ AT Week 24 | |
Active Non-responders on PF-06651600 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.1 | 0.0 |
Active Non-responders on PF-06700841 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.1 | 0.0 |
Placebo Non-responders on PF-06651600 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.8 | 17.6 |
Placebo Non-responders on PF-06700841 | 0.0 | 0.0 | 0.0 | 8.3 | 25.0 | 33.3 | 47.9 | 50.0 |
Retreated PF-06651600 Responders in the Retreatment Segment | 0.0 | 0.0 | 0.0 | 7.1 | 14.3 | 21.4 | 26.4 | 28.6 |
Retreated Responders on PF-06700841 in the Retreatment Segment | 0.0 | 0.0 | 0.0 | 6.7 | 13.3 | 20.0 | 24.5 | 40.0 |
SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method. (NCT02974868)
Timeframe: Baseline, Weeks 2,4,6,8,12,16,20,24
Intervention | percentage of participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Week 2 | Week 4 | Week 6 | Week 8 | Week 12 | Week 16 | Week 20 | Week 24 | |
PF-06651600 | 0.0 | 0.0 | 0.0 | 4.2 | 10.4 | 16.7 | 18.7 | 25.0 |
PF-06700841 | 0.0 | 0.0 | 6.4 | 12.8 | 25.5 | 27.7 | 29.8 | 34.0 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 2.1 | 0 |
Time to re-treatment (weeks) = (date of re-treatment criteria met - date at Week 24 +1)/7. The calendar time to retreatment was calculated. Baseline is defined as Week 24 measurement. The duration in Drug Holiday #1 (ranging from 2-6 weeks) is counted in the Kaplan-Meier analysis. One subject directly entered the re-treatment period and hence is censored at baseline in the Kaplan-Meier analysis. (NCT02974868)
Timeframe: Week 24 up to Week 52
Intervention | Weeks (Number) | ||
---|---|---|---|
Q1 time to retreatment (25th percentile of time) | Median time to retreatment | Q3 time to retreatment (75th percentile of time) | |
PF-06651600 Responders | 10.1 | 16.1 | 21.1 |
PF-06700841 Responders | 11.0 | 24.1 | NA |
The clinical evaluator of alopecia areata (AA) will perform an assessment of the overall improvement of AA and assign an Investigator Global Assessment (IGA) score(ranging from 0 to 5) with higher score representing higher regrowth rate. Baseline is defined as the last measurement prior to first dosing (Day 1). (NCT02974868)
Timeframe: baseline, Week 2,4,6,8,12,16,20,24
Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline72539794 | Baseline72539793 | Baseline72539795 | Week 272539793 | Week 272539794 | Week 272539795 | Week 472539793 | Week 472539794 | Week 472539795 | Week 672539793 | Week 672539794 | Week 672539795 | Week 872539793 | Week 872539795 | Week 872539794 | Week 1272539794 | Week 1272539795 | Week 1272539793 | Week 1672539793 | Week 1672539794 | Week 1672539795 | Week 2072539793 | Week 2072539794 | Week 2072539795 | Week 2472539793 | Week 2472539794 | Week 2472539795 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
0 (NO CHANGE OR FURTHER LOSS) | 1 (1-24% REGROWTH) | 2 (25-49% REGROWTH) | 3 (50-74% REGROWTH) | 4 (75-99% REGROWTH) | 5 (100% REGROWTH) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 48 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 47 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 47 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 40 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 40 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 36 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 33 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Placebo | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06700841 | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PF-06651600 | 6 |
Patients came back for follow-up every month during a total of 24 weeks of treatments and at weeks 28,36 and 48. (NCT03800979)
Timeframe: 48 weeks
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Dyslipidemia | Upper respiratory tract infection | Tuberculosis | Myalgia | Acne | Weight gain | Constipation | |
Tofacitinib | 9 | 6 | 1 | 1 | 2 | 1 | 1 |
28 reviews available for salicylic acid and Alopecia Circumscripta
Article | Year |
---|---|
[Janus kinase inhibitors for the treatment of alopecia areata].
Topics: Alopecia; Alopecia Areata; Humans; Janus Kinase Inhibitors; Quality of Life; Scalp | 2022 |
Trichoscopy beyond scalp. A narrative review.
Topics: Alopecia Areata; Eyebrows; Hair; Humans; Scalp; Scalp Dermatoses | 2023 |
Alopecia Areata: Current Treatments and New Directions.
Topics: Alopecia; Alopecia Areata; Hair Follicle; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors; | 2023 |
Alopecia Areata: The Clinician and Patient Voice.
Topics: Alopecia; Alopecia Areata; Autoimmune Diseases; Hair Follicle; Humans; Recurrence; Scalp | 2023 |
Common causes of hair loss - clinical manifestations, trichoscopy and therapy.
Topics: Alopecia; Alopecia Areata; Hair Diseases; Humans; Lichen Planus; Scalp; Trichotillomania | 2021 |
Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus.
Topics: Alopecia Areata; Antimalarials; Dermatologic Agents; Dermoscopy; Diagnosis, Differential; Disease Pr | 2018 |
Alopecia areata: A multifactorial autoimmune condition.
Topics: Adrenal Cortex Hormones; Alopecia; Alopecia Areata; Animals; Autoimmunity; Cell Movement; Gene-Envir | 2019 |
The role of the microbiome in scalp hair follicle biology and disease.
Topics: Alopecia; Alopecia Areata; Animals; Dermatitis, Seborrheic; Hair; Hair Follicle; Humans; Immune Syst | 2020 |
Alopecia areata: more than skin deep.
Topics: Alopecia Areata; Global Health; Hair; Humans; Prevalence; Scalp | 2013 |
Hair loss in autoimmune systemic diseases.
Topics: Alopecia; Alopecia Areata; Autoimmune Diseases; Cicatrix; Connective Tissue Diseases; Hair Diseases; | 2014 |
Central centrifugal cicatricial alopecia: what has been achieved, current clues for future research.
Topics: Alopecia Areata; Black or African American; Cicatrix; Female; Humans; Prevalence; Risk Factors; Scal | 2014 |
Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination.
Topics: Alopecia; Alopecia Areata; Beauty Culture; Diagnosis, Differential; Humans; Hyperandrogenism; Physic | 2014 |
Circumscribed cicatricial alopecia due to localized sarcoidal granulomas and single-organ granulomatous arteritis: a case report and systematic review of sarcoidal vasculitis.
Topics: Acyclovir; Adult; Aged; Alopecia Areata; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; B | 2015 |
Evaluation of hair loss.
Topics: Alopecia; Alopecia Areata; Biopsy; Dermatitis, Seborrheic; Dermoscopy; Female; Hair Diseases; Humans | 2015 |
Scalp dermoscopy or trichoscopy.
Topics: Alopecia; Alopecia Areata; Cicatrix; Dermoscopy; Hair Diseases; Humans; Lupus Erythematosus, Discoid | 2015 |
Alopecia areata.
Topics: Alopecia Areata; Environmental Exposure; Hair; Hair Follicle; Humans; Microbiota; Scalp; Stress, Psy | 2017 |
Coexistence of giant blue nevus of the scalp with hair loss and alopecia areata.
Topics: Adult; Alopecia Areata; Humans; Male; Nevus, Blue; Scalp; Skin Neoplasms; Tomography, X-Ray Computed | 2011 |
Ant-induced alopecia: report of 2 cases and review of the literature.
Topics: Adult; Alopecia; Alopecia Areata; Animals; Ants; Appetitive Behavior; Bedding and Linens; Diagnosis, | 2004 |
Congenital alopecia areata.
Topics: Administration, Cutaneous; Alopecia Areata; Eyebrows; Eyelashes; Female; Follow-Up Studies; Glucocor | 2005 |
Alopecia neoplastica simulating alopecia areata and antedating the detection of primary breast carcinoma.
Topics: Adult; Alopecia; Alopecia Areata; Breast Neoplasms; Diagnosis, Differential; Female; Humans; Scalp; | 1994 |
Does interleukin-1 induce hair loss?
Topics: Alopecia Areata; Animals; Gene Expression Regulation; Hair; Humans; Immunologic Factors; Interleukin | 1995 |
Scalp metastases mimicking alopecia areata. First case report of placental site trophoblastic tumor presenting as cutaneous metastasis.
Topics: Adult; Alopecia Areata; Diagnosis, Differential; Female; Humans; Postpartum Period; Pregnancy; Scalp | 1998 |
Cicatricial pemphigoid rarely involves the scalp.
Topics: Alopecia Areata; Biopsy; Female; Humans; Middle Aged; Pemphigoid, Benign Mucous Membrane; Scalp; Tre | 1998 |
Double-lined frontoparietal scleroderma en coup de sabre.
Topics: Adult; Alopecia Areata; Female; Humans; Scalp; Scleroderma, Localized | 1999 |
Recent developments in alopecias.
Topics: Alopecia; Alopecia Areata; Androgens; Dihydrotestosterone; Female; Humans; Male; Protein-Energy Maln | 1978 |
3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Chronic Disease; Clinical Trials as Topic; Double-B | 1988 |
Common hair disorders.
Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Humans; Male; Nevus, Pigmented; Scalp; Skin Neoplas | 1986 |
Alopecia: syndromes of genetic significance.
Topics: Abnormalities, Multiple; Adolescent; Adult; Age Factors; Alopecia; Alopecia Areata; Child; Child, Pr | 1973 |
17 trials available for salicylic acid and Alopecia Circumscripta
Article | Year |
---|---|
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
Topics: Alopecia; Alopecia Areata; Biomarkers; Humans; Janus Kinase Inhibitors; Protein Kinase Inhibitors; S | 2022 |
The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double-blind placebo-controlled trial.
Topics: Alopecia; Alopecia Areata; Double-Blind Method; Humans; Latanoprost; Scalp; Treatment Outcome | 2022 |
The role of autologous micrografts injection from the scalp tissue in the treatment of COVID-19 associated telogen effluvium: Clinical and trichoscopic evaluation.
Topics: Adult; Alopecia Areata; Autografts; COVID-19; Follow-Up Studies; Hair Follicle; Humans; Microsurgery | 2022 |
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.
Topics: Alopecia Areata; Biomarkers; Humans; Keratins, Hair-Specific; Scalp; Virulence | 2023 |
Use of vibrating anesthetic device reduces the pain of mesotherapy injections: A randomized split-scalp study.
Topics: Alopecia; Alopecia Areata; Anesthetics; Child; Humans; Mesotherapy; Pain; Scalp | 2021 |
A randomized, placebo and active controlled, split scalp study to evaluate the efficacy of platelet-rich plasma in patchy alopecia areata of the scalp.
Topics: Alopecia Areata; Humans; Platelet-Rich Plasma; Scalp; Treatment Outcome; Triamcinolone Acetonide | 2020 |
Identification of novel step-up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double-blind randomized controlled trial.
Topics: Alopecia Areata; Humans; Injections, Intralesional; Scalp; Treatment Outcome; Triamcinolone Acetonid | 2021 |
Treatment of androgenetic alopecia with 5-aminolevulinic acid photodynamic therapy: A randomized, placebo-controlled, split-scalp study of efficacy and safety.
Topics: Alopecia Areata; Aminolevulinic Acid; Humans; Photochemotherapy; Photosensitizing Agents; Scalp; Tre | 2021 |
Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study.
Topics: Administration, Cutaneous; Adult; Alopecia Areata; Bimatoprost; Dermatologic Agents; Female; Hair; H | 2015 |
Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study.
Topics: Adult; Alopecia Areata; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration S | 2015 |
Intralesional Triamcinolone Acetonide Versus Topical Betamethasone Valearate in the Management of Localized Alopecia Areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Betamethasone Valerate; Female; Follow-Up Studies; | 2015 |
Multiple courses of pulse corticosteroid therapy for alopecia areata.
Topics: Administration, Intravenous; Adolescent; Adult; Alopecia Areata; Female; Glucocorticoids; Hair; Huma | 2016 |
Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata.
Topics: Administration, Topical; Adolescent; Alopecia Areata; Anthralin; Child; Chronic Disease; Dermatologi | 2017 |
Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata.
Topics: Administration, Topical; Adolescent; Adult; Aged; Alopecia Areata; Anticarcinogenic Agents; Bexarote | 2009 |
Treatment effects of intradermal botulinum toxin type A injection on alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Botulinum Toxins, Type A; Child; Female; Humans; Injections, Int | 2010 |
Cytokine mRNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone.
Topics: Adult; Aged; Allergens; Alopecia Areata; Biopsy; Chromatography, High Pressure Liquid; Cyclopropanes | 1994 |
3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata.
Topics: Administration, Topical; Adult; Alopecia Areata; Chronic Disease; Clinical Trials as Topic; Double-B | 1988 |
251 other studies available for salicylic acid and Alopecia Circumscripta
Article | Year |
---|---|
Resident human dermal γδT-cells operate as stress-sentinels: Lessons from the hair follicle.
Topics: Adult; Aged; Alopecia Areata; Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Autoim | 2021 |
Characterizing the willingness to undergo treatment in patients with alopecia areata.
Topics: Administration, Topical; Alopecia; Alopecia Areata; Hair; Humans; Scalp | 2022 |
Nonscarring scalp alopecia: Which laboratory analysis should we perform on whom?
Topics: Alopecia; Alopecia Areata; Female; Ferritins; Hemoglobins; Humans; Male; Retrospective Studies; Scal | 2022 |
Telogen Effluvium as a complication of scalp reconstruction with tissue expander: a case report.
Topics: Alopecia Areata; Female; Humans; Scalp; Surgical Flaps; Tissue Expansion; Tissue Expansion Devices | 2021 |
A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measures.
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Female; Hair; Humans; Male; Nail Diseases; Patient Rep | 2022 |
Alopecia areata - Current understanding and management.
Topics: Alopecia; Alopecia Areata; Humans; Immunotherapy; Quality of Life; Recurrence; Scalp | 2022 |
Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Hair; Humans; Quality of Life; Scalp | 2023 |
Rare Concurrence of Alopecia Areata in the Setting of the Lipedematous Scalp.
Topics: Alopecia; Alopecia Areata; Glycyrrhizic Acid; Humans; Lipedema; Minoxidil; Scalp; Vitamin D | 2022 |
Changing spectrum of hair and scalp disorders over the last decade in a tertiary medical centre.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Alopecia Areata; Child; Child, Preschool; Fema | 2023 |
Annular plaque over the scalp with patchy alopecia.
Topics: Alopecia; Alopecia Areata; Humans; Scalp; Scalp Dermatoses | 2023 |
The First Evidence of Bacterial Foci in the Hair Part and Dermal Papilla of Scalp Hair Follicles: A Pilot Comparative Study in Alopecia Areata.
Topics: Adult; Alopecia Areata; Hair Follicle; Humans; Microbiota; Middle Aged; Scalp; Young Adult | 2022 |
Trichoscopic Diagnosis of Structural Hair Defects in a Clinical Setting: A Cross-Sectional Analytical Study.
Topics: Alopecia Areata; Cross-Sectional Studies; Dermoscopy; Female; Hair; Humans; Male; Scalp | 2023 |
Trichoscopic Diagnosis of Structural Hair Defects in a Clinical Setting: A Cross-Sectional Analytical Study.
Topics: Alopecia Areata; Cross-Sectional Studies; Dermoscopy; Female; Hair; Humans; Male; Scalp | 2023 |
Trichoscopic Diagnosis of Structural Hair Defects in a Clinical Setting: A Cross-Sectional Analytical Study.
Topics: Alopecia Areata; Cross-Sectional Studies; Dermoscopy; Female; Hair; Humans; Male; Scalp | 2023 |
Trichoscopic Diagnosis of Structural Hair Defects in a Clinical Setting: A Cross-Sectional Analytical Study.
Topics: Alopecia Areata; Cross-Sectional Studies; Dermoscopy; Female; Hair; Humans; Male; Scalp | 2023 |
Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores.
Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Hair; Humans; Male; Retrospective Studies; Scalp | 2023 |
Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores.
Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Hair; Humans; Male; Retrospective Studies; Scalp | 2023 |
Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores.
Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Hair; Humans; Male; Retrospective Studies; Scalp | 2023 |
Automating Hair Loss Labels for Universally Scoring Alopecia From Images: Rethinking Alopecia Scores.
Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Hair; Humans; Male; Retrospective Studies; Scalp | 2023 |
Scalp capillarectasia as a trichoscopic sign of COVID-19-associated telogen effluvium.
Topics: Alopecia Areata; COVID-19; Humans; Scalp | 2023 |
Granuloma annulare with alopecia areata in a 6-year-old girl: a case report.
Topics: Alopecia Areata; Child; Female; Glucocorticoids; Granuloma Annulare; Humans; Scalp | 2023 |
Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series.
Topics: Alopecia; Alopecia Areata; Cicatrix; Humans; Lichen Planus; Sarcoidosis; Scalp | 2023 |
Integrated single-cell chromatin and transcriptomic analyses of human scalp identify gene-regulatory programs and critical cell types for hair and skin diseases.
Topics: Alopecia Areata; Chromatin; Eczema; Genome-Wide Association Study; Hair Follicle; Humans; Scalp; Tra | 2023 |
Diagnosis and differential diagnosis of tertiary androgenetic alopecia with severe alopecia areata based on high-resolution MRI.
Topics: Alopecia; Alopecia Areata; Diagnosis, Differential; Hair Follicle; Humans; Magnetic Resonance Imagin | 2023 |
Adjuvant Scalp Rolling for Patients With Refractory Alopecia Areata.
Topics: Adjuvants, Immunologic; Alopecia Areata; Humans; Scalp | 2023 |
Immunohistochemistry of a cellular infiltrate in a case of nivolumab-induced alopecia areata.
Topics: Alopecia Areata; Humans; Immunohistochemistry; Nivolumab; Scalp | 2023 |
There are early, gradual and late responders for scalp hair regrowth in patients with alopecia areata treated with baricitinib.
Topics: Alopecia Areata; Hair; Humans; Scalp | 2023 |
Increased expression of TLR7 and TLR9 in alopecia areata.
Topics: Adult; Alopecia Areata; Autoimmune Diseases; Biopsy; Female; Hair Follicle; Humans; Interferon-gamma | 2020 |
Combined and dynamic trichoscopic signs for diagnosis and follow-up of inflammatory tinea capitis.
Topics: Alopecia Areata; Antifungal Agents; Child, Preschool; Female; Humans; Scalp; Tinea Capitis; Treatmen | 2020 |
Response of alopecia areata of the beard to oral tofacitinib.
Topics: Administration, Oral; Adult; Aged; Alopecia Areata; Cheek; Chin; Humans; Janus Kinases; Male; Middle | 2020 |
Long-standing patchy alopecia areata along the hairline, a variety of alopecia areata mimicking frontal fibrosing alopecia and other cases of hair loss: case series of 11 patients.
Topics: Adult; Alopecia Areata; Biopsy; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Scalp | 2020 |
The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Hair; Humans; Scalp | 2020 |
Local secretion of stress hormones increases in alopecia areata lesions after treatment with UVA-1 phototherapy.
Topics: Adrenocorticotropic Hormone; Adult; Alopecia Areata; alpha-MSH; Biopsy; Corticotropin-Releasing Horm | 2020 |
Development of the Scalp Hair Assessment PRO™ measure for alopecia areata.
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Hair; Humans; North America; Patient Reported Outcome | 2020 |
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing.
Topics: Alopecia; Alopecia Areata; Humans; Janus Kinase 3; Lichen Planus; Quality of Life; Scalp | 2020 |
Percentage of scalp-hair loss as a primary endpoint in alopecia areata trials.
Topics: Alopecia Areata; Hair Follicle; Humans; Scalp | 2020 |
Predictive Metagenomic Profiling, Urine Metabolomics, and Human Marker Gene Expression as an Integrated Approach to Study Alopecia Areata.
Topics: Alopecia Areata; Biomarkers; Gene Expression; Humans; Metabolomics; Scalp | 2020 |
Massive Acute Alopecia of the Scalp in a Patient Treated with Dupilumab.
Topics: Alopecia Areata; Antibodies, Monoclonal, Humanized; Humans; Scalp | 2020 |
A new self-reported measure of disease severity of scalp hair loss in alopecia areata.
Topics: Alopecia; Alopecia Areata; Hair; Humans; Scalp; Self Report; Severity of Illness Index | 2020 |
Clinically Applicable Deep Learning Framework for Measurement of the Extent of Hair Loss in Patients With Alopecia Areata.
Topics: Alopecia Areata; Deep Learning; Hair; Humans; Image Processing, Computer-Assisted; Photography; Prog | 2020 |
Exome sequencing reveals novel candidate gene variants associated with clinical characteristics in alopecia areata patients.
Topics: Acyltransferases; Adolescent; Age of Onset; Alopecia; Alopecia Areata; Child; Chloride Channels; Exo | 2020 |
Does dysfunctional autophagy contribute to immune privilege collapse and alopecia areata pathogenesis?
Topics: Adult; Alopecia Areata; Apoptosis; Autophagy; Biopsy; Case-Control Studies; Dietary Supplements; Fem | 2020 |
Expression of survivin and p53 genes in patients with alopecia areata: A case-control study.
Topics: Adolescent; Adult; Alopecia Areata; Biopsy, Needle; Case-Control Studies; Female; Genes, p53; Humans | 2021 |
Topics: Alopecia Areata; Gastrointestinal Microbiome; Genomics; Humans; Microbiota; Scalp | 2020 |
Scalp sarcoidosis with alopecia areata showing Renbök phenomenon.
Topics: Alopecia; Alopecia Areata; Humans; Psoriasis; Sarcoidosis; Scalp | 2020 |
[Regulatory T cells control hair growth and prevent the development of alopecia areata].
Topics: Alopecia Areata; Hair; Hair Follicle; Humans; Scalp; Skin Physiological Phenomena; T-Lymphocytes, Re | 2020 |
Trichoscopy of Alopecia Areata: Hair Loss Feature Extraction and Computation Using Grid Line Selection and Eigenvalue.
Topics: Algorithms; Alopecia Areata; Computational Biology; Dermoscopy; Disease Progression; Hair; Hair Foll | 2020 |
Role of adiponectin and leptin in patients with alopecia areata with scalp hair loss.
Topics: Adiponectin; Alopecia Areata; Body Mass Index; Case-Control Studies; Female; Humans; Insulin Resista | 2021 |
Eyebrows Are Important in the Treatment of Alopecia Areata.
Topics: Adult; Alopecia Areata; Eyebrows; Female; Hair; Humans; Male; Middle Aged; Patient Care Planning; Pa | 2020 |
Monitoring Response to Platelet-Rich Plasma in Patients with Alopecia Areata with Optical Coherence Tomography: A Case Series.
Topics: Aged; Alopecia; Alopecia Areata; Biological Factors; Female; Hair; Humans; Male; Middle Aged; Platel | 2020 |
The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Endpoint Determination; Extremities; Eye Diseases; Eyebrow | 2020 |
Co-localization of alopecia areata and lichen planopilaris in a patient receiving immunosuppressants: A rare case.
Topics: Adult; Alopecia; Alopecia Areata; Female; Hair Follicle; Humans; Immunosuppressive Agents; Lichen Pl | 2021 |
Scalp Micropigmentation Procedure: A Useful Procedure for Hair Restoration.
Topics: Alopecia Areata; Cicatrix; Female; Hair; Humans; Male; Scalp; Tattooing | 2021 |
Diphenylcyclopropenone plays an effective therapeutic role by up-regulating the TSLP/OX40L/IL-13 pathway in severe alopecia areata.
Topics: Administration, Cutaneous; Adolescent; Adult; Alopecia Areata; Child; Cyclopropanes; Cytokines; Derm | 2021 |
Trichobiolight: A new, effective protocol in the treatment of androgenetic alopecia and telogen effluvium.
Topics: Alopecia; Alopecia Areata; Female; Hair; Humans; Italy; Male; Middle Aged; Scalp | 2021 |
Lesson to Learn From Cellular infiltrate in Scalp Biopsy of Alopecia Areata.
Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Female; Humans; Male; Middle Aged; Scalp; Young Adult | 2021 |
An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata.
Topics: Alopecia Areata; Biomarkers; Humans; Keratins, Hair-Specific; Keratins, Type II; Lymphocyte Activati | 2021 |
Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement.
Topics: Alopecia; Alopecia Areata; Biomarkers; Cross-Sectional Studies; Female; Fibrosis; Humans; Lichen Pla | 2022 |
Alopecia areata severity index (AASI): A reliable scoring system to assess the severity of alopecia areata on face and scalp-a pilot study.
Topics: Alopecia Areata; Hair; Humans; Pilot Projects; Reproducibility of Results; Scalp | 2021 |
Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study.
Topics: Alopecia; Alopecia Areata; Female; Humans; Lichen Planus; Middle Aged; Retrospective Studies; Scalp; | 2021 |
Lupus erythematosus tumidus of the scalp masquerading as alopecia areata.
Topics: Alopecia Areata; Biopsy; Female; Humans; Lupus Erythematosus, Discoid; Middle Aged; Scalp | 2017 |
Treatment of Alopecia Areata With Tofacitinib.
Topics: Adult; Alopecia Areata; Female; Follow-Up Studies; Hair; Humans; Male; Middle Aged; Piperidines; Pol | 2017 |
Pediatric severity of alopecia tool.
Topics: Adolescent; Alopecia Areata; Child; Child, Preschool; Disease Progression; Female; Hair; Humans; Mal | 2018 |
Correlation of vitamin D and vitamin D receptor expression in patients with alopecia areata: a clinical paradigm.
Topics: Adult; Alopecia Areata; Biopsy; Case-Control Studies; Female; Hair Follicle; Humans; Male; Prospecti | 2018 |
Quantifying Alopecia Areata via Texture Analysis to Automate the SALT Score Computation.
Topics: Algorithms; Alopecia Areata; Child; Diagnosis, Computer-Assisted; Female; Hair; Humans; Image Proces | 2018 |
Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients.
Topics: Alopecia Areata; Biopsy; Case-Control Studies; Cytokines; Enzyme-Linked Immunosorbent Assay; Humans; | 2018 |
Adalimumab-related alopecia in a patient affected by psoriasis.
Topics: Adalimumab; Alopecia; Alopecia Areata; Anti-Inflammatory Agents; Biopsy; Diagnosis, Differential; Hu | 2017 |
Correlation between serum IL-17A level and SALT score in patients with alopecia areata before and after NB-UVB therapy.
Topics: Adolescent; Adult; Age Factors; Alopecia Areata; Case-Control Studies; Child; Female; Humans; Interl | 2018 |
An integrated model of alopecia areata biomarkers highlights both T
Topics: Adult; Aged; Alopecia Areata; Biomarkers; Cytokines; Female; Humans; Male; Middle Aged; Scalp; Th1 C | 2018 |
Utility of Horizontal Sections of Scalp Biopsies in Differentiating between Androgenetic Alopecia and Alopecia Areata.
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Biopsy; Cross-Sectional Studies; Female; Hair Follicle | 2018 |
Morphological classification system of hair regrowth patterns in alopecia areata patches: DIMT classification.
Topics: Alopecia Areata; Hair; Humans; Photography; Retrospective Studies; Scalp | 2019 |
High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Animals; Autoimmune Diseases; CD8-Positive T-Lymphocytes; Diseas | 2018 |
Sequential cyclic changes of hair roots revealed by dermoscopy demonstrate a progressive mechanism of diffuse alopecia areata over time.
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Biopsy; Case-Control Studies; Dermoscopy; Female; Hair | 2020 |
Cellular retinol-binding protein-1 expression increases with increasing clinical severity of alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Case-Control Studies; Child; Female; Humans; Male; Middl | 2019 |
A prospective study of tinea capitis in children: making the diagnosis easier with a dermoscope.
Topics: Adolescent; Alopecia Areata; Child; Child, Preschool; Dermoscopy; Female; Hair; Humans; Male; Prospe | 2018 |
Rule of thumb: A simple tool to estimate 1% scalp surface area.
Topics: Adult; Alopecia Areata; Body Surface Area; Clinical Trials as Topic; Dermatology; Female; Humans; Ma | 2019 |
Use of trichoscopy for the diagnosis of alopecia areata coexisting with primary scarring alopecia in a female hair loss patient.
Topics: Adult; Alopecia Areata; Cicatrix; Dermoscopy; Diagnosis, Differential; Female; Hair; Humans; Scalp | 2019 |
Scalp bacterial shift in Alopecia areata.
Topics: Adult; Alopecia Areata; Case-Control Studies; DNA, Bacterial; Dysbiosis; Female; Humans; Male; Micro | 2019 |
The profile of cytokines (IL-2, IFN-γ, IL-4, IL-10, IL-17A, and IL-23) in active alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Cytok | 2020 |
Integrative analysis of rare copy number variants and gene expression data in alopecia areata implicates an aetiological role for autophagy.
Topics: Alopecia Areata; Autophagy; Autophagy-Related Proteins; Cysteine Endopeptidases; DNA Copy Number Var | 2020 |
The effect of platelet rich plasma on hair regrowth in patients with alopecia areata totalis: A clinical pilot study.
Topics: Adolescent; Adult; Alopecia Areata; Female; Hair; Humans; Male; Pilot Projects; Platelet-Rich Plasma | 2019 |
Method for describing patterns and distributions of alopecia areata which may be helpful for patient characterization and predicting prognosis.
Topics: Administration, Topical; Adolescent; Alopecia Areata; Child; Cryotherapy; Female; Follow-Up Studies; | 2019 |
Treatment of alopecia areata with nonablative fractional laser combined with topical minoxidil.
Topics: Administration, Topical; Adult; Alopecia; Alopecia Areata; Child; Combined Modality Therapy; Female; | 2019 |
Nanoparticle Targeting to Scalp Hair Follicles: New Perspectives for a Topical Therapy for Alopecia Areata.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Alopecia Areata; Drug Delivery Systems; Hai | 2020 |
Trichoscopy of alopecia areata in children. A retrospective comparative analysis of 50 children and 50 adults.
Topics: Adult; Age Factors; Alopecia Areata; Child; Child, Preschool; Dermoscopy; Female; Hair Follicle; Hum | 2019 |
Combination of tacalcitol ointment and photodynamic therapy for the treatment of follicular mucinosis of the scalp.
Topics: Alopecia Areata; Aminolevulinic Acid; Dermatologic Agents; Dihydroxycholecalciferols; Drug Therapy, | 2019 |
Dupilumab and alopecia: A Janus effect.
Topics: Adult; Alopecia Areata; Antibodies, Monoclonal, Humanized; Dose-Response Relationship, Drug; Humans; | 2019 |
Granulomatous alopecia: a variant of alopecia areata?
Topics: Adult; Aged; Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Female; Glucocor | 2013 |
Clinical and histopathological features of itch in patients with alopecia areata.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Arachidonate 5-Lipoxygenase; Biopsy; Ca | 2013 |
Prominent follicular mucinosis with diffuse scalp alopecia resembling alopecia areata.
Topics: Alopecia Areata; Anti-Inflammatory Agents; Diagnosis, Differential; Female; Humans; Middle Aged; Muc | 2013 |
Trichoscopy in paediatric patients with tinea capitis: a useful method to differentiate from alopecia areata.
Topics: Alopecia Areata; Child; Child, Preschool; Dermoscopy; Diagnosis, Differential; Female; Hair; Humans; | 2014 |
Vitiligo and alopecia areata: apples and oranges?
Topics: Adult; Alopecia Areata; Autoimmune Diseases; Dermatology; Humans; Inflammation; Male; Melanocytes; S | 2013 |
Sudden onset hair loss and colour change.
Topics: Acute Disease; Alopecia Areata; Biopsy; Diagnosis, Differential; Hair Color; Hair Follicle; Humans; | 2013 |
Congenital temporal triangular alopecia: a typical Brauer nevus.
Topics: Alopecia Areata; Child; Dermoscopy; Follow-Up Studies; Humans; Male; Monitoring, Physiologic; Nevus; | 2013 |
Graves' disease associated with alopecia areata developing after Hashimoto's thyroiditis.
Topics: Adult; Alopecia Areata; Female; Graves Disease; Hashimoto Disease; Humans; Scalp; Ultrasonography | 2013 |
Patches of hair loss on the occipital scalp.
Topics: Adolescent; Alopecia Areata; Atrophy; Biopsy; Dermoscopy; Hair Follicle; Humans; Intensive Care Unit | 2014 |
Scalp conditions.
Topics: Alopecia Areata; Antifungal Agents; Child; Child, Preschool; Female; Glucocorticoids; Griseofulvin; | 2015 |
Detailed clinicopathological characterization of progressive alopecia areata patients treated with i.v. corticosteroid pulse therapy toward optimization of inclusion criteria.
Topics: Adolescent; Adult; Alopecia Areata; Female; Glucocorticoids; Humans; Male; Methylprednisolone; Middl | 2014 |
Colocalization of vitiligo and alopecia areata presenting as poliosis.
Topics: Alopecia Areata; Child; Diagnosis, Differential; Humans; Male; Scalp; Vitiligo | 2015 |
An observational study of alopecia areata in Sri Lankan adult patients.
Topics: Adolescent; Adult; Age of Onset; Alopecia Areata; Autoimmune Diseases; Female; Humans; Male; Middle | 2014 |
Hair dye: a trichoscopy pitfall.
Topics: Alopecia Areata; Color; Dermoscopy; Diagnosis, Differential; Diagnostic Errors; Hair Dyes; Humans; S | 2015 |
Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata.
Topics: Adult; Alopecia Areata; Case-Control Studies; Female; Forkhead Transcription Factors; Humans; Lympho | 2015 |
Assessment of tissue levels of dickkopf-1 in androgenetic alopecia and alopecia areata.
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Case-Control Studies; Female; Humans; Intercellular Si | 2016 |
Annular alopecia areata: a morphologically rare variant.
Topics: Adolescent; Alopecia Areata; Autoimmune Diseases; Humans; Male; Scalp | 2015 |
Biomarkers of alopecia areata disease activity and response to corticosteroid treatment.
Topics: Adrenal Cortex Hormones; Alopecia Areata; Biomarkers; Biopsy; Cytokines; Female; Gene Expression Pro | 2016 |
Alopecia Areata Progression Index, a Scoring System for Evaluating Overall Hair Loss Activity in Alopecia Areata Patients with Pigmented Hair: A Development and Reliability Assessment.
Topics: Adolescent; Adult; Alopecia Areata; Child; Dermoscopy; Disease Progression; Female; Hair Color; Huma | 2016 |
Vasoactive intestinal peptide, whose receptor-mediated signalling may be defective in alopecia areata, provides protection from hair follicle immune privilege collapse.
Topics: Alopecia Areata; Epithelium; Female; Hair Follicle; Healthy Volunteers; Humans; Interferon-gamma; Pi | 2016 |
Follicular mucinosis with diffuse scalp alopecia treated with narrow-band UVB phototherapy: the role of trichoscopy in monitoring therapeutic outcomes.
Topics: Alopecia Areata; Dermoscopy; Female; Humans; Middle Aged; Mucinosis, Follicular; Scalp; Treatment Ou | 2016 |
Reflectance confocal microscopy for scarring and non-scarring alopecia real-time assessment.
Topics: Alopecia Areata; Biopsy; Cicatrix; Dermoscopy; Diagnosis, Differential; Female; Humans; Lichen Planu | 2016 |
Investigation on the role of necroptosis in alopecia areata: A preliminary study.
Topics: Adult; Alopecia Areata; Apoptosis; Autophagy; Female; Humans; Male; Necrosis; Receptor-Interacting P | 2016 |
Trichoscopy as a useful method to differentiate tinea capitis from alopecia areata in children at Zagazig University Hospitals.
Topics: Alopecia Areata; Child; Child, Preschool; Dermoscopy; Diagnosis, Differential; Egypt; Female; Hair; | 2017 |
Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprehensive review of 353 cases over 22 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Child; Child, Preschool; Cryotherapy; F | 2017 |
Dermal Titanium Dioxide Deposition Associated With Intralesional Triamcinolone Injection.
Topics: Administration, Cutaneous; Alopecia Areata; Biopsy; Drug Compounding; Glucocorticoids; Humans; Injec | 2016 |
Trichoscopic clues for diagnosis of alopecia areata and trichotillomania in Asians.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Asian People; Child; Dermoscopy; Diagno | 2017 |
Efficacy of superficial cryotherapy on the eyebrows of patients with alopecia universalis also treated with contact immunotherapy on the scalp: a prospective, split-face comparative study.
Topics: Adolescent; Adult; Alopecia Areata; Child; Cryotherapy; Cyclopropanes; Eyebrows; Female; Hair; Human | 2017 |
Direct Immunofluorescence studies of patients with alopecia areata in affected and clinically normal areas of scalp.
Topics: Adult; Aged; Aged, 80 and over; Alopecia Areata; Biopsy; Complement C3; Female; Fluorescent Antibody | 2009 |
Value of transverse section scalp biopsy in alopecia areata - a clinicopathological correlation.
Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Child; Child, Preschool; Cross-Sectional Studies; Female | 2008 |
The alpha-melanocyte stimulating hormone-related tripeptide K(D)PT stimulates human hair follicle pigmentation in situ under proinflammatory conditions.
Topics: Aged; Alopecia Areata; alpha-MSH; Female; Hair Color; Hair Follicle; Hormones; Humans; Interleukin-1 | 2009 |
Decreased heme oxygenase-1 expression in the scalp of patients with alopecia areata: the pathogenic role of heme oxygenase-1.
Topics: Adolescent; Adult; Alopecia Areata; Child; Female; Gene Expression; Heme Oxygenase-1; Humans; Male; | 2009 |
Treatment of alopecia areata with fractional photothermolysis laser.
Topics: Adult; Alopecia Areata; Hair; Humans; Low-Level Light Therapy; Male; Scalp | 2010 |
Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe.
Topics: Adrenal Cortex Hormones; Adult; Alopecia Areata; Anticholesteremic Agents; Drug Therapy, Combination | 2010 |
Type 1 interferon signature in the scalp lesions of alopecia areata.
Topics: Alopecia Areata; Hair Follicle; Humans; Interferon Type I; Lichen Planus; Lupus Erythematosus, Disco | 2010 |
Melanocortin receptor type 2 (MC2R, ACTH receptor) expression in patients with alopecia areata.
Topics: Adult; Alopecia Areata; Cell Membrane; Cytoplasm; Dermis; Epidermal Cells; Epidermis; Female; Hair F | 2010 |
'Follicular Swiss cheese' pattern--another histopathologic clue to alopecia areata.
Topics: Alopecia Areata; Humans; Scalp | 2011 |
Treatment of alopecia areata with 308-nm excimer lamp.
Topics: Adult; Aged; Alopecia Areata; Erythema; Female; Hair; Humans; Lasers, Excimer; Low-Level Light Thera | 2010 |
Letter: Cerebriform intradermal nevus presenting as secondary cutis verticis gyrata.
Topics: Alopecia Areata; Diagnosis, Differential; Head and Neck Neoplasms; Humans; Male; Melanosis; Middle A | 2010 |
Reflectance confocal microscopy of the yellow dot pattern in alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Dermoscopy; Female; Hair Follicle; Humans; Male; Microsc | 2011 |
JAAD Grand Rounds quiz. Fixed focal alopecia for 20 years.
Topics: Adult; Alopecia; Alopecia Areata; Diagnosis, Differential; Hair Follicle; Humans; Male; Scalp | 2011 |
Calcitonin gene-related peptide (CGRP) may award relative protection from interferon-γ-induced collapse of human hair follicle immune privilege.
Topics: Alopecia Areata; Calcitonin Gene-Related Peptide; Calcitonin Receptor-Like Protein; Hair Follicle; H | 2012 |
Association between scalp psoriasis and alopecia areata.
Topics: Adult; Alopecia Areata; Humans; Male; Psoriasis; Scalp | 2012 |
'Black dots' seen under trichoscopy are not specific for alopecia areata.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Child; Child, Preschool; Dermoscopy; Female; Humans; Male; | 2012 |
Congenital combined melanocytic nevus of the scalp with associated alopecia areata.
Topics: Alopecia Areata; Biomarkers, Tumor; Biopsy; Head and Neck Neoplasms; Humans; Immunohistochemistry; M | 2013 |
Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids.
Topics: Absorptiometry, Photon; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Alopecia Areata; Anti-Inf | 2013 |
Analysis of the expression of cutaneous lymphocyte-associated antigen on the peripheral blood and cutaneous lymphocytes of alopecia areata patients.
Topics: Adolescent; Adult; Alopecia Areata; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Bio | 2002 |
Panniculitis-like T-cell lymphoma clinically manifested as alopecia.
Topics: Alopecia Areata; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphoma, T-Cell, Cutan | 2002 |
[Postmenopausal frontal fibrosing alopecia. Report of 3 cases].
Topics: Aged; Alopecia Areata; Diagnosis, Differential; Female; Humans; Lupus Erythematosus, Discoid; Middle | 2002 |
Borderline tuberculoid leprosy and alopecia areata involving scalp.
Topics: Adult; Alopecia Areata; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy, Tuberculoid; | 2002 |
Linear scleroderma en coup de sabre and brain calcification: is there a pathogenic relationship?
Topics: Adult; Alopecia Areata; Calcinosis; Epilepsy, Tonic-Clonic; Female; Humans; Occipital Lobe; Scalp; S | 2003 |
Striae distensae-like lesions. A cause of scarring alopecia among children.
Topics: Alopecia Areata; Atrophy; Child; Child, Preschool; Cicatrix; Diagnosis, Differential; Female; Humans | 2002 |
Computerized morphometry and three-dimensional image reconstruction in the evaluation of scalp biopsy from patients with non-cicatricial alopecias.
Topics: Adolescent; Adult; Aged; Alopecia; Alopecia Areata; Biopsy; Female; Hair Follicle; Humans; Image Pro | 2003 |
Transfer of alopecia areata in the human scalp graft/Prkdc(scid) (SCID) mouse system is characterized by a TH1 response.
Topics: Alopecia Areata; Animals; Cytokines; HLA-DR Antigens; Humans; Intercellular Adhesion Molecule-1; Mic | 2003 |
Localized scalp hair shedding caused by Pheidole ants and overwiew of similar case reports.
Topics: Adolescent; Adult; Alopecia Areata; Animals; Ants; Ectoparasitic Infestations; Female; Humans; Male; | 2003 |
Alopecia areata and other common scalp problems.
Topics: Alopecia; Alopecia Areata; Disease; Humans; Hyaluronoglucosaminidase; Hydrocortisone; Scalp; Skin Di | 1958 |
Noncicatrizing alopecias; with special reference to alopecia areata.
Topics: Adrenal Cortex Hormones; Adult; Alopecia; Alopecia Areata; Dermatologic Agents; Female; Glucocortico | 1958 |
[Data on vascular spasm in the pathogenesis of various cases of alopecia areata].
Topics: Alopecia; Alopecia Areata; Cardiovascular System; Humans; Scalp; Spasm; Vascular Diseases | 1961 |
Nerve network of the hair follicle in alopecia areata.
Topics: Alopecia; Alopecia Areata; Hair Follicle; Humans; Scalp | 1960 |
[Circumscribed lichenification of the hair of the head with simultaneous reversible alopecia].
Topics: Alopecia; Alopecia Areata; Disease; Hair; Head; Humans; Scalp; Skin Diseases | 1960 |
[Lupus erythematosus of the scalp with characteristics of alopecia areata].
Topics: Alopecia; Alopecia Areata; Disease; Humans; Lupus Erythematosus, Systemic; Medical Records; Scalp; S | 1961 |
[Apropos of a case of chronic trichophytosis of the scalp, of pseudo-pelada type, due to Trichophyton verrucosum].
Topics: Alopecia; Alopecia Areata; Humans; Scalp; Tinea; Tinea Capitis; Trichophyton | 1962 |
FLUOCINOLONE ACETONIDE IN PROPYLENE GLYCOL.
Topics: Adrenal Cortex Hormones; Alopecia; Alopecia Areata; Dermatitis; Dermatitis, Atopic; Dermatitis, Sebo | 1963 |
[CIRCUMSCRIBED NONMYCOTIC ALOPECIA-LIKE DISEASES OF THE SCALP IN CHILDREN].
Topics: Alopecia; Alopecia Areata; Child; Classification; Humans; Scalp; Scalp Dermatoses | 1965 |
[Hair loss].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alopecia; Alopecia Areata; Biopsy; Child; Clinical Tria | 2003 |
Histopathologic features of alopecia areata: a new look.
Topics: Adult; Aged; Alopecia Areata; Biopsy; Computer Graphics; Female; Humans; Male; Middle Aged; Prospect | 2003 |
Tinea capitis in a 17 year old soldier (residual infection?); alopecia areata associated with tinea capitis?
Topics: Alopecia; Alopecia Areata; Humans; Microsporum; Military Personnel; Scalp; Tinea; Tinea Capitis | 1950 |
[Alopecia areata and occipital angioma: fortuitous association or predictive factor?].
Topics: Alopecia Areata; Hemangioma; Humans; Scalp; Skin Neoplasms | 2004 |
Histopathological pictures of the initial changes of the hair bulbs in alopecia areata.
Topics: Adolescent; Alopecia Areata; Biopsy; Hair Follicle; Humans; Male; Scalp | 2004 |
Videodermatoscopy enhances diagnostic capability in some forms of hair loss.
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Child; Child, Preschool; Female; Hair; Hair Follicle; | 2004 |
Interleukin-2 receptor alpha-chain expression in patients with alopecia areata.
Topics: Adult; Aged; Alopecia Areata; Female; Humans; Immunohistochemistry; Lymphocyte Activation; Male; Mid | 2004 |
[Circumscribed alopecia following furunculosis].
Topics: Alopecia; Alopecia Areata; Animals; Furunculosis; Humans; Scalp | 1950 |
Alopecia areata universalis sparing nevus flammeus.
Topics: Adult; Alopecia Areata; Diagnosis, Differential; Humans; Male; Mosaicism; Port-Wine Stain; Scalp | 2005 |
[Excimer laser therapy of alopecia areata--side-by-side evaluation of a representative area].
Topics: Adult; Alopecia Areata; Follow-Up Studies; Hair; Humans; Low-Level Light Therapy; Male; Prospective | 2005 |
Acute alopecia totalis.
Topics: Adult; Alopecia Areata; Female; Glucocorticoids; Hair; Humans; Male; Methylprednisolone; Pulse Thera | 2006 |
Thorium X and skin cancer: still a problem in the 21st century.
Topics: Alopecia Areata; Carcinoma, Basal Cell; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm | 2007 |
Alopecia areata associated with basal cell carcinoma developing within a naevus sebaceus.
Topics: Adult; Alopecia Areata; Carcinoma, Basal Cell; Hamartoma; Humans; Male; Scalp; Scalp Dermatoses; Ski | 2006 |
Multifocal scalp hair loss.
Topics: Adult; Alopecia Areata; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Ca | 2006 |
Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells.
Topics: Alopecia Areata; Drug Resistance; Hair Follicle; Humans; Hydrogen Peroxide; Immunohistochemistry; Re | 2007 |
Changes in distribution pattern of CD8 lymphocytes in the scalp in alopecia areata during treatment with diphencyprone.
Topics: Adolescent; Adult; Alopecia Areata; Biopsy; CD8-Positive T-Lymphocytes; Cell Movement; Cyclopropanes | 2007 |
Dry dermoscopy in clinical treatment of alopecia areata.
Topics: Adult; Alopecia Areata; Dermoscopy; Diagnosis, Differential; Female; Hair; Hair Follicle; Humans; Ma | 2007 |
Hair loss in children in South-East Nigeria: common and uncommon cases.
Topics: Adolescent; Age Distribution; Alopecia; Alopecia Areata; Child; Child, Preschool; Female; Humans; In | 2007 |
A case of widespread non-pigmented hair regrowth in diffuse alopecia areata.
Topics: Alopecia Areata; Eyebrows; Female; Glucocorticoids; Hair; Hair Color; Humans; Middle Aged; Pigmentat | 2007 |
Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack.
Topics: Adolescent; Adult; Alopecia Areata; CD4 Antigens; CD56 Antigen; CD8 Antigens; CD8-Positive T-Lymphoc | 2008 |
The role of scalp dermoscopy in the diagnosis of alopecia areata incognita.
Topics: Adult; Alopecia Areata; Biopsy; Dermoscopy; Female; Humans; Male; Scalp | 2008 |
Immunofluorescent studies of complement C3 in the hair follicles of normal scalp and of scalp affected by alopecia areata.
Topics: Adult; Aged; Alopecia Areata; Complement C3; Female; Fluorescent Antibody Technique; Hair; Humans; I | 1980 |
[Comparative morphometric study of the sebaceous and sweat glands in alopecia areata, chronic diffuse and seborrheic baldness].
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Biopsy; Child; Chronic Disease; Dermatitis, Seborrheic | 1982 |
Immunohistochemical and electron microscopic characterization of the cellular infiltrate in alopecia (areata, totalis, and universalis).
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Antibodies, Monoclonal; Child; Child, Preschool; Femal | 1984 |
T cell subpopulations in alopecia areata.
Topics: Adult; Alopecia Areata; Antibodies, Monoclonal; Child; Female; Fluorescent Antibody Technique; Hair; | 1984 |
Subcutaneous blood flow in alopecia areata.
Topics: Adult; Aged; Alopecia Areata; Female; Humans; Male; Middle Aged; Regional Blood Flow; Scalp | 1984 |
[Clinical and electron microscopy study of alopecia areata].
Topics: Alopecia Areata; Biopsy; Hair; Humans; Microscopy, Electron; Scalp | 1984 |
Immunopathological studies on alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Autoantibodies; Endothelium; Epidermis; Female; Fluorescent Anti | 1980 |
[Surgical treatment in some types of alopecia (author's transl)].
Topics: Adult; Alopecia; Alopecia Areata; Female; Humans; Male; Scalp | 1981 |
[Alopecia].
Topics: Adult; Alopecia; Alopecia Areata; Child; Female; Hair; Humans; Lupus Erythematosus, Systemic; Male; | 1980 |
HLA and ICAM-1 expression in alopecia areata in vivo and in vitro: the role of cytokines.
Topics: Alopecia Areata; Cell Adhesion Molecules; Cytokines; Granulocyte-Macrophage Colony-Stimulating Facto | 1993 |
Alopecia universalis in a patient with psoriasis vulgaris.
Topics: Alopecia Areata; Autoimmune Diseases; CD4-Positive T-Lymphocytes; Humans; Male; Middle Aged; Psorias | 1995 |
Abnormalities in the ultrastructure of melanocytes and the outer root sheath of clinically normal hair follicles from alopecia areata scalps.
Topics: Alopecia Areata; Cytoplasmic Granules; Epidermis; Epithelium; Hair; Humans; Melanocytes; Scalp | 1995 |
Immunity to hair follicles in alopecia areata.
Topics: Alopecia Areata; Autoantibodies; Autoantigens; Autoimmune Diseases; Hair; Humans; Immunoglobulin G; | 1995 |
T-cell receptor repertoire V beta in alopecia areata.
Topics: Alopecia; Alopecia Areata; Case-Control Studies; Gene Expression; Genetic Variation; Hair; Humans; L | 1995 |
Histopathology of alopecia areata in horizontal sections of scalp biopsies.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Biopsy; Child; Child, Preschool; Female; Hair; Humans; Inf | 1995 |
Glucocorticoid regulation of hair growth in alopecia areata.
Topics: Alopecia; Alopecia Areata; Calcium; Calmodulin; Case-Control Studies; Glucocorticoids; Hair; Humans; | 1995 |
Is the dermal papilla a primary target in alopecia areata?
Topics: Alopecia Areata; Autoantibodies; Autoimmune Diseases; Basement Membrane; CD4-Positive T-Lymphocytes; | 1995 |
Clinical and histologic findings in temporal triangular alopecia.
Topics: Adolescent; Adult; Alopecia; Alopecia Areata; Biopsy; Diagnosis, Differential; Female; Hair; Humans; | 1994 |
[Bilateral linear temporoparietal scleroderma en coup de sabre].
Topics: Adult; Alopecia Areata; Autoantibodies; Collagen; Diagnosis, Differential; Female; Hair; Humans; Sca | 1994 |
[Alopecia areata and diffuse hypotrichosis associated with Ullrich-Turner syndrome. Presentation of 4 patients].
Topics: Adult; Alopecia Areata; Female; Hair; Humans; Hypotrichosis; Scalp; Turner Syndrome | 1993 |
Pulse of methylprednisolone in alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Drug Administration Schedule; Drug Tolerance; Face; Female; Foll | 1993 |
Pseudopelade of Brocq is lichen planopilaris: report of four cases that support this nosology.
Topics: Adult; Aged; Alopecia Areata; Female; Humans; Lichen Planus; Male; Middle Aged; Scalp; Scalp Dermato | 1993 |
Hairy pigmented congenital naevocellular naevus in a patient with alopecia universalis.
Topics: Adolescent; Alopecia Areata; Female; Humans; Nevus, Pigmented; Scalp; Skin Neoplasms | 1993 |
Alopecia areata in a patient with candidiasis-endocrinopathy syndrome: unsuccessful treatment trial with diphenylcyclopropenone.
Topics: Adolescent; Adult; Alopecia Areata; Child; Child, Preschool; Cyclopropanes; Follow-Up Studies; Hair; | 1995 |
No correlation between cytomegalovirus and alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Cytomegalovirus; DNA, Viral; Humans; In Situ Hybridization; Scal | 1996 |
Ultrastructural abnormalities in the dermal papillae of both lesional and clinically normal follicles from alopecia areata scalps.
Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Hair Follicle; Humans; Microscopy, Electron; Middle Aged | 1996 |
Differential T-cell reactivity to the round and oval forms of Pityrosporum in the skin of patients with psoriasis.
Topics: Adult; Alopecia Areata; Autoantibodies; CD4-Positive T-Lymphocytes; Cell Line; Cell Wall; Cytoplasm; | 1997 |
Possible involvement of neuropeptidergic sensory nerves in alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Biopsy; Calcitonin Gene-Related Peptide; Case-Control Studies; H | 1997 |
Eosinophils in fibrous tracts and near hair bulbs: a helpful diagnostic feature of alopecia areata.
Topics: Alopecia Areata; Biopsy; Eosinophils; Hair; Hair Follicle; Humans; Scalp | 1997 |
Nonscarring alopecia associated with solitary circumscribed neuroma.
Topics: Aged; Alopecia Areata; Female; Humans; Neuroma; Scalp; Skin Neoplasms | 1997 |
Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice.
Topics: Adult; Alopecia Areata; Animals; Autoimmune Diseases; Cells, Cultured; Female; HLA-DR Antigens; Huma | 1998 |
[Temporary roentgen epilation after embolization of a cerebral arteriovenous malformation].
Topics: Adult; Alopecia Areata; Cerebral Angiography; Dose-Response Relationship, Radiation; Embolization, T | 1998 |
Localised alopecia of the scalp. Common causes.
Topics: Adolescent; Alopecia; Alopecia Areata; Child; Humans; Infant, Newborn; Scalp; Tinea Capitis; Trichot | 1998 |
Pronounced perifollicular lymphocytic infiltrates in alopecia areata are associated with poor treatment response to diphencyprone.
Topics: Administration, Topical; Alopecia Areata; Case-Control Studies; Cyclopropanes; Hair Follicle; Humans | 1999 |
Diagnosis: alopecia areata or not?
Topics: Adolescent; Alopecia Areata; Biopsy; Diagnosis, Differential; Female; Humans; Middle Aged; Scalp | 1999 |
Nurse's cap alopecia.
Topics: Adult; Alopecia Areata; Female; Hair Follicle; Humans; Korea; Microscopy, Electron; Middle Aged; Nur | 1999 |
Temporary hair loss simulating alopecia areata after endovascular surgery of cerebral arteriovenous malformations: a report of 3 cases.
Topics: Adult; Alopecia Areata; Diagnosis, Differential; Embolization, Therapeutic; Female; Humans; Intracra | 1999 |
Role of cytotoxic T cells in chronic alopecia areata.
Topics: Alopecia Areata; Antigens, CD; Chronic Disease; Cytokines; HLA-DR Antigens; Humans; Immunohistochemi | 2000 |
Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I.
Topics: Alopecia Areata; Autoantibodies; Autoantigens; Europe; Gene Library; Humans; Isoenzymes; Polyendocri | 2000 |
Characterization of infiltrating T cells in human scalp explants from alopecia areata to SCID nude mice: possible role of the disappearance of CD8+ T lymphocytes in the process of hair regrowth.
Topics: Adult; Alopecia Areata; Animals; CD4-CD8 Ratio; Female; Hair; HLA-DR Antigens; Humans; Immunohistoch | 1999 |
Migratory poliosis: A forme fruste of alopecia areata?
Topics: Adult; Alopecia Areata; Black People; Cell Movement; Hair Color; Humans; Male; Scalp | 2000 |
Expression of neuropeptide-degrading enzymes in alopecia areata: an immunohistochemical study.
Topics: Adult; Alopecia Areata; E-Selectin; Endothelium, Vascular; Female; Hair Follicle; Humans; Immunoenzy | 2001 |
Functional analysis of the stratum corneum of scalp skin: studies in patients with alopecia areata and androgenetic alopecia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Alopecia Areata; Cheek; Child; Female; Forearm | 2000 |
Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice.
Topics: Adult; Alopecia Areata; Animals; Autoantigens; Cell Extracts; Epitopes, T-Lymphocyte; Female; Hair F | 2001 |
Antioxidant enzymes and lipid peroxidation in the scalp of patients with alopecia areata.
Topics: Adult; Alopecia Areata; Glutathione Peroxidase; Humans; Lipid Peroxides; Male; Scalp; Superoxide Dis | 2002 |
Dinitrochlorobenzene therapy for alopecia areata.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Child; Dinitrochlorobenzene; Drug Eruptions; Female; Human | 1978 |
[Deposits of complement C3 in the hair follicle of normal scalp and alopecia areata (author's transl)].
Topics: Adult; Aged; Alopecia Areata; Complement C3; Female; Hair; Humans; Male; Scalp | 1979 |
[Aplasia cutis circumscripta congenita].
Topics: Acute Disease; Alopecia Areata; Dermatologic Surgical Procedures; Diagnosis, Differential; Female; H | 1977 |
[Immunohistological study of alopecia areata (author's transl)].
Topics: Adolescent; Adult; Alopecia Areata; Child; Child, Preschool; Female; Fluorescent Antibody Technique; | 1979 |
Alopecia areata: immunofluorescence and other studies.
Topics: Adolescent; Adult; Alopecia Areata; Autoantibodies; Child; Female; Humans; Immunoglobulins; Male; Mi | 1978 |
Diagnosing the common alopecias.
Topics: Alopecia; Alopecia Areata; Biopsy; Humans; Lupus Erythematosus, Discoid; Scalp; Tinea Capitis; Trich | 1978 |
[The histodynamic of alopecia areata in the dependence on the griseofulvin-induced epithelial proliferation (author's transl)].
Topics: Alopecia Areata; Cell Division; Epithelium; Griseofulvin; Hair; Humans; Scalp | 1978 |
Cellular activity in the dermis surrounding the hair bulb in alopecia areata.
Topics: Alopecia Areata; Connective Tissue; Connective Tissue Cells; DNA; Epithelial Cells; Epithelium; Fema | 1975 |
Alopecia areata.
Topics: Alopecia Areata; Female; Humans; Middle Aged; Scalp | 1975 |
Follicular mucinosis in alopecia areata.
Topics: Adolescent; Alopecia Areata; Female; Humans; Immunohistochemistry; Mucinosis, Follicular; Scalp; T-L | 1992 |
The transverse anatomy of androgenic alopecia.
Topics: Alopecia Areata; Frozen Sections; Hair; Humans; Male; Scalp; Staining and Labeling | 1990 |
Expression of tenascin in perifollicular connective tissue: comparison of normal scalp and alopecia areata.
Topics: Alopecia Areata; Cell Adhesion Molecules, Neuronal; Connective Tissue; Extracellular Matrix Proteins | 1991 |
The ultrastructure of the dermal papilla-epithelial junction in normal and alopecia areata hair follicles.
Topics: Alopecia Areata; Biopsy; Epithelium; Hair; Humans; Intercellular Junctions; Reference Values; Scalp | 1991 |
Evidence for a subclinical state of alopecia areata.
Topics: Alopecia Areata; Biopsy; Female; Hair; Humans; Male; Reference Values; Scalp | 1991 |
Transient defects in cortical cell differentiation form the exclamation-mark shaft in acute alopecia areata.
Topics: Acute Disease; Adult; Alopecia Areata; Cell Differentiation; Hair; Humans; Microscopy, Electron; Mic | 1991 |
Three distinct patterns of cell degeneration in acute alopecia areata.
Topics: Acute Disease; Alopecia Areata; Cell Death; Hair; Humans; Keratinocytes; Microscopy, Electron; Necro | 1991 |
Cryosectioning of hair follicles. An improved method using liquid nitrogen conduction freezing.
Topics: Alopecia Areata; Biopsy; Freezing; Hair; Hair Diseases; Humans; Immunohistochemistry; Nitrogen; Scal | 1990 |
[Asymptomatic increase in the telogen rate].
Topics: Adult; Alopecia Areata; Diagnosis, Differential; Female; Hair Diseases; Humans; Scalp | 1991 |
[Temporal arteritis with scalp and tongue necrosis and brain stem infarct].
Topics: Aged; Alopecia Areata; Brain Stem; Cerebral Infarction; Diagnosis, Differential; Female; Giant Cell | 1990 |
Haemorheological parameters in alopecia areata.
Topics: Adolescent; Adult; Alopecia Areata; Blood Viscosity; Child; Erythrocyte Deformability; Female; Human | 1985 |
Increase of mast cells in the alopecia lesion of mice.
Topics: Alopecia Areata; Animals; Cell Count; Hair; Humans; Mast Cells; Mice; Mice, Inbred Strains; Scalp; S | 1985 |
Alopecia areata incognita: a hypothesis.
Topics: Alopecia Areata; Androgens; Dermatitis, Seborrheic; Hair; Humans; Scalp; Stochastic Processes | 1987 |
In situ lymphocyte subsets in alopecia areata before and during treatment with a contact allergen.
Topics: Adult; Aged; Alopecia Areata; Dinitrochlorobenzene; Female; Humans; Lymphocytes; Male; Middle Aged; | 1987 |
Corroborative evidence that alopecia areata involves the epidermis and the sebaceous glands.
Topics: Adult; Alopecia Areata; Autoradiography; Epidermis; Female; Hair; Humans; Male; Scalp; Sebaceous Gla | 1987 |
Quantification of scalp hair--a computer-aided methodology.
Topics: Alopecia Areata; Analog-Digital Conversion; Hair; Humans; Photography; Scalp; Statistics as Topic | 1986 |
Hair growth in scalp grafts from patients with alopecia areata and alopecia universalis grafted onto nude mice.
Topics: Alopecia; Alopecia Areata; Animals; Cyclosporins; Female; Graft Survival; Hair; Humans; Male; Mice; | 1987 |
Hair loss. Common congenital and acquired causes.
Topics: Adolescent; Alopecia; Alopecia Areata; Androgens; Child; Diagnosis, Differential; Female; Hair; Huma | 1986 |
[Aplasia cutis congenita and foetus papyraceus].
Topics: Adult; Alopecia Areata; Female; Fetal Diseases; Humans; Infant, Newborn; Placenta; Placenta Diseases | 1985 |
Epidemic alopecia areata. An outbreak in an industrial setting.
Topics: Adult; Alopecia Areata; Biopsy; Breast; Canada; Dermatitis, Occupational; Disease Outbreaks; Environ | 1971 |
Cutaneous corticosteroid injection and amaurosis. Analysis for cause and prevention.
Topics: Alopecia Areata; Blindness; Blood Pressure; Embolism; Eye; Female; Humans; Hydrocortisone; Injection | 1974 |
[Determination of vascular flow in peladic patches with xenon 133].
Topics: Alopecia Areata; Hemodynamics; Humans; Methods; Radioisotopes; Regional Blood Flow; Scalp; Skin; Xen | 1972 |
Regrowth of hair in nevus flammeus.
Topics: Alopecia Areata; Female; Hair; Hemangioma; Humans; Middle Aged; Regional Blood Flow; Scalp | 1972 |
[Basal cell carcinomas of the hairy head simulating "alopecia areata"].
Topics: Adult; Alopecia Areata; Carcinoma, Basal Cell; Diagnosis, Differential; Female; Humans; Male; Middle | 1972 |
Tonsure trichotillomania.
Topics: Adolescent; Adult; Alopecia Areata; Depression; Diagnosis, Differential; Female; Hair; Humans; Middl | 1970 |
Can scalp hair suddenly turn white? A case of canities subita.
Topics: Alopecia Areata; Hair; Humans; Male; Middle Aged; Pigmentation; Scalp | 1970 |
[Are there any connections between sensory innervation of the head and location of the alopecia areata foci?].
Topics: Alopecia Areata; Autonomic Nervous System; Humans; Peripheral Nerves; Scalp; Time Factors | 1970 |
[Chronic diffuse lupus erythematosus of the head with enormous horny protuberances and decalvant pelada].
Topics: Alopecia Areata; Face; Head; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Scalp | 1967 |
The blood vessels of the scalp in patients with alopecia areata before and after corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Alkaline Phosphatase; Alopecia; Alopecia Areata; Biopsy; Hair; Humans; Hydr | 1968 |
[Study of the apparently normal scalp in alopecia areata].
Topics: Adolescent; Adult; Alopecia Areata; Child; Child, Preschool; Female; Humans; Male; Middle Aged; Scal | 1965 |
[Hair root pattern in psoriasis vulgaris of the scalp].
Topics: Adolescent; Adult; Aged; Alopecia Areata; Child; Child, Preschool; Female; Hair; Hair Removal; Human | 1966 |